Patent Application
20240067982
A Sequence Listing accompanies this application and is submitted as an xml file of the sequence listing named “702581_02062.xml” which is 176,408 bytes in size and was created on Jun. 8, 2023. The sequence listing is electronically submitted via Patent Center and is incorporated herein by reference in its entirety.
The field of the invention relates to methods, kits, and compositions for modifying DNA. In particular, the field of the invention relates to components and methods for RNA-directed DNA cleavage and gene editing.
Genome editing has proven to be quite difficult in cells, particularly in mammalian cells. One way to improve genome-editing efficiency is to introduce a double-strand break (DSB) in the desired DNA region. DSBs stimulate the DNA repair machinery and, in the presence of a homologous repair template, greatly enhance genome editing efficiency. Currently, there are two widely used systems to introduce targeted DSBs in genomes of mammalian cells—Zinc Finger Nucleases (ZFNs) and Transcription activator-like effector nucleases (TALENs), both of which are engineered by fusing site-specific DNA recognition domains to Fokl endonucleases. One major obstacle to the wide application of these two systems is the difficulty of engineering peptides that recognize specific target DNA sites. Also, for each unique target sequence, a different pair of ZFNs or TALENs has to be engineered. For ZFNs, the optimal designing algorithm is proprietary and only available through commercial sources. For TALENs, the design rules are quite straightforward, but it still takes weeks to make one pair of targeting constructs, and each must be adequately expressed and validated.
Clustered, regularly interspaced short palindromic repeats (CRISPRs) are known in the art (see Marraffini and Sontheimer, Nature Reviews Vol. 11, Mach 2010, 181-190, U.S. Published Patent Application No. 2010/0076057, and U.S. Pat. No. 8,697,359, which are incorporated herein by reference in their entireties), and have been utilized for genome editing (see Cain, SciBX, Vol. 6, No. 4, January 2010, 1-7). Recently, CRISPR RNAs (crRNAs) have been developed that direct DNA cleavage by a bacterial protein called Cas9. (See Cong et al., Science, Vol. 339, Feb. 15, 2013, 819-822; and Mali et al., Science, Vol. 339, Feb. 15, 2013, 823-826). This system requires only three components: a Cas9 endonuclease, a trans-activating CRISPR RNA (tracrRNA), and the target-specifying crRNA which hybridizes to a target DNA sequence and targets the DNA sequence for cleavage by the Cas9 endonuclease. Accordingly, nearly any genomic locus can be targeted by the same Cas9 protein, as long as a crRNA complementary to the targeted sequence is provided. Two Cas9 proteins (SpCas9 from Streptococcus pyogenes and StCas9 from Streptococcus thermophilus) have been reported as effective in genome editing, and each has its own targeting sequence requirements. However, there is a need for the identification of new systems in order to maximize the potential of CRISPR as a gene editing tool.
Here, we report a new form of Cas9 (NmCas9 from Neisseria meningitidis) that has distinct targeting requirements which are less likely to result in off-target effects. Furthermore, unlike SpCas9 and StCas9, NmCas9 can function with crRNAs that are embedded within longer unprocessed precursors, indicating that NmCas9 can accommodate a greater range of targeting crRNA structures and functionalities. In addition, mutant forms of NmCas9 can be used that bind DNA in an RNA-directed fashion, but that do not cleave the DNA.
Disclosed are methods and components for RNA-directed DNA cleavage and gene editing. The methods utilize components including a Cas9 protein from Neisseria and one or more RNA molecules in order to direct the Cas9 protein to bind to and optionally cleave or nick a target sequence.
In some embodiments, the methods modify a target DNA sequence in a cell and may include: (a) expressing a Cas9 protein from a Neisseria species or a variant protein thereof in the cell (e.g., by transfecting the cell with a DNA molecule or an RNA molecule that expresses the Cas9 protein (i.e., Cas9 mRNA)); and (b) transfecting the cell with an RNA molecule or expressing an RNA molecule in the cell from a DNA molecule, wherein the RNA molecule binds to the Cas9 protein or variant, and the RNA molecule hybridizes to the target DNA sequence. Optionally, the Cas9 protein or variant protein has nuclease activity (e.g., DNase activity and/or RNase activity) and cleaves one (i.e., nicks) or both strands of the target DNA sequence. Optionally, the methods further comprise contacting the target DNA sequence with a homologous DNA fragment, wherein homologous recombination is induced between the homologous DNA fragment and the target DNA sequence (e.g., homologous recombination to effect gene repair or to effect gene disruption). In further embodiments, the Cas9 protein or variant protein has no nuclease activity (e.g., no DNAse activity) and binds to the target DNA sequence but does not cleave the DNA sequence.
In some embodiments, the Cas9 protein or variant protein is encoded and expressed by a nucleic acid having a codon sequence that is optimized for expression in the cell. For example, the nucleic acid may have a codon sequence that is optimized for expression in an animal cell (e.g., a human or non-human mammalian cell). The Cas9 protein may be expressed from an expression vector comprising a prokaryotic or eukaryotic promoter for expressing the Cas9 protein which is transfected into the cell.
Suitable Cas9 proteins may include, but are not limited to, Cas9 proteins from Neisseria species (e.g., Neisseria meningitidis). Variants of Cas9 proteins may include proteins having an amino acid sequence that has at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to an amino acid sequence of a Cas9 protein. Optionally, the variant has one or more biological activities associated with the Cas9 protein (e.g., nuclease activity and RNA binding activity).
The methods may be utilized to target a DNA sequence in a cell. Suitable cells may include prokaryotic cells and eukaryotic cells. In some embodiments, the methods are performed to target a DNA sequence in a stem cell (e.g., an embryonic stem cell or an induced pluripotent stem cell).
The methods typically utilize an RNA molecule that comprises a sequence that hybridizes with a target DNA sequence in a cell. The RNA molecule also binds with the Cas9 protein or a variant thereof. In some embodiments, the RNA molecule comprises two molecules of duplexed RNA (e.g., crRNA duplexed with tracRNA). In other embodiments, the RNA molecule is a single RNA molecule forming a hairpin structure (e.g., where crRNA is linked to tracRNA via a linker such as GAAA and the crRNA and tracRNA form the stem of the hairpin). In further embodiments, the RNA may include an RNA mimic of green fluorescent protein (GFP). As such, the RNA may be utilized to map a target DNA sequence via adding 4-hydroxybenzylidene (HPD), 3,5-dimethoxy-4-hydroxybenzylidene (DMHPD), or a 3,5-difluoro-4-hydroxybenzylidene to the cell (DFHPD), wherein the RNA binds to HPD, DMHPD, or DFHPD to form a fluorescent complex. In further embodiments, the RNA may comprise Xist RNA or fragments thereof, which may be utilized to modulate the expression of the target DNA sequence. The RNA may be transfected directly into a cell and/or may be expressed from an expression vector comprising a prokaryotic or eukaryotic promoter for expressing the RNA when the expression vector is transfected into the cell.
Also disclosed are proteins, polynucleotides, vectors, and kits for performing the disclosed methods. For example, a contemplated protein may include the Neisseria meningitidis Cas9 protein or a variant thereof. A contemplated polynucleotide may comprise a eukaryotic promoter operably linked to a polynucleotide sequence encoding a Cas9 protein from a Neisseria species or a variant thereof (e.g., a Cas9 protein fused to one or more of a nuclear localization signal (NLS), a ligand for purifying the variant protein, and a tag for identifying the variant protein). The polynucleotide may be present in a vector for propagating the polynucleotide or expressing the polynucleotide (e.g. a prokaryotic and/or eukaryotic vector).
The contemplated kits may comprise any of the presently disclosed proteins, polynucleotides, and vectors. A kit may comprise: (a) a polynucleotide for expressing a Cas9 protein from a Neisseria species or a variant protein thereof in a cell (e.g., as part of an expression vector comprising a eukaryotic promoter for expressing the Cas9 protein or alternatively as Cas9 mRNA); and (b) RNA that binds to the Cas9 protein or variant and RNA that hybridizes to the target DNA sequence in the cell (e.g., as a single RNA or as multiple RNAs, or as a DNA vector or vectors that expresses the single or multiple RNAs).
Also contemplated herein are cells that are transformed or transfected with the polynucleotides or vectors contemplated herein. Suitable cells may include prokaryotic and eukaryotic cells.
The present invention is described herein using several definitions, as set forth below and throughout the application.
Unless otherwise specified or indicated by context, the terms “a”, “an”, and “the” mean “one or more.” For example, “a protein” or “an RNA” should be interpreted to mean “one or more proteins” or “one or more RNAs,” respectively.
As used herein, “about,” “approximately,” “substantially,” and “significantly” will be understood by persons of ordinary skill in the art and will vary to some extent on the context in which they are used. If there are uses of these terms which are not clear to persons of ordinary skill in the art given the context in which they are used, “about” and “approximately” will mean plus or minus≤10% of the particular term and “substantially” and “significantly” will mean plus or minus≥10% of the particular term.
As used herein, the terms “include” and “including” have the same meaning as the terms “comprise” and “comprising” in that these latter terms are “open” transitional terms that do not limit claims only to the recited elements succeeding these transitional terms. The term “consisting of,” while encompassed by the term “comprising,” should be interpreted as a “closed” transitional term that limits claims only to the recited elements succeeding this transitional term. The term “consisting essentially of,” while encompassed by the term “comprising,” should be interpreted as a “partially closed” transitional term which permits additional elements succeeding this transitional term, but only if those additional elements do not materially affect the basic and novel characteristics of the claim.
Disclosed are methods that utilize and kits and compositions that comprise components for RNA-directed DNA cleavage and gene editing. The methods typically utilize and the kits and composition typically comprise a Cas9 protein, or a variant protein thereof, and RNA that hybridizes to a target DNA sequence. The Cas9 protein and RNA typically bind and form a complex with the target DNA sequence. The Cas9 protein may have nuclease activity (e.g., DNAse activity and/or RNase activity) and may cleave one (i.e., nick) or both strands of the target DNA sequence. The term “nick” will be understood as an interruption in the covalent continuity of one strand of a double-stranded nucleic acid molecule. The term “nick’ can also describe an enzymatic activity that results in the production of a nick in a nucleic acid molecule. The disclosed methods may be utilized for RNA-directed DNA cleavage in vitro, RNA-directed genome editing in vivo, and RNA-directed genome binding by Cas9 proteins.
CRISPR/Cas is a recently discovered, adaptive, sequence-based immune system identified in bacteria and archaea. A “Type II” CRISPR/Cas system from Streptococcus pyogenes SF370 has been developed into a simple eukaryotic genome editing tool. This system requires only three components: Ca9 endonuclease, a trans-activating CRISPR RNA (tracrRNA), and the target-specifying crRNA. By fusing the crRNA and tracrRNA into a single transcript referred to as an sgRNA, the machinery can be further streamlined into a two-component system. The target DNA sequence that base-pairs with the crRNA is referred to as the “protospacer.” The two nuclease domains (RuvC and HNH) of Cas9 each cleave one DNA target strand and thus induce a DSB. Cleavage by Cas9 also depends on the presence of a short motif called a protospacer adjacent motif (PAM) that flanks the target region recognized by crRNA base pairing.
The present inventors have demonstrated that the Neisseria meningitidis (Nm) Cas9/crRNA/tracrRNA system can work efficiently for genome editing in human embryonic stem cells (hESCs), leaving behind small insertions and deletions. They have also shown that the NmCas9-induced DSB can serve as a site of transgene insertion. They have mapped the NmCas9 cleavage site to the third and fourth base pairs of the protospacer, at the end closest to the PAM. Importantly, the Cas9/crRNA/tracrRNA system uses the same Cas9 protein and tracrRNA for every targeting event. Only one component—the crRNA—needs to be customized for each individual target, which makes the system very user-friendly.
In addition to these in vivo advances, the inventors have shown that recombinant NmCas9 can be expressed in E. coli cells and that it can catalyze crRNA-directed DNA cleavage in vitro. This could enable enhanced recombinant DNA capabilities.
The inventors have also demonstrated that the NmCas9 system, in its native bacterial context, has a novel feature: It can function with long, unprocessed crRNA precursors. In bacterial cells, Type II CRISPR/Cas systems generate pre-crRNAs that are cleaved by a protein called RNase III. In N. meningitidis, deletion of the rnc gene that encodes RNase III has no deleterious effect on the CRISPR pathway, unlike all other Type II systems examined to date. In vitro experiments have confirmed that unprocessed crRNAs can direct DNA cleavage by NmCas9. Together these indicate that NmCas9 can tolerate extensions on its cognate crRNAs without loss of function, which SpCas9 and StCas9 cannot, perhaps enabling expanded functionality by fusing the crRNAs to other useful RNAs such as RNA mimics (see Paige et al., Science, 29 Jul. 2011) and Xist RNA or fragments thereof (see Plath et al., Annu Rev Genet. 2002; 36:233-78 Epub 2002 Jun. 11).
The inventors have also demonstrated that the NmCas9 system has distinct PAM requirements versus Type II CRISPR/Cas systems from different bacteria. For example, for SpCas9 the PAM is 5′-NGG3′, while for NmCas9, the PAM is 5′-NNNNGATT3′ (in both cases the dash represents the terminal nucleotide of the crRNA-paired sequence). Thus, the presently disclosed methods will open up potential target sites that are not cleavable with existing systems. Also, the specificity for genome editing may increase with a longer PAM.
The present inventors have identified a novel Cas9 protein. As used herein, the terms “protein” or “polypeptide” or “peptide” may be used interchangeably to refer to a polymer of amino acids. Typically, a “polypeptide” or “protein” is defined as a longer polymer of amino acids, of a length typically of greater than 50, 60, 70, 80, 90, or 100 amino acids. A “peptide” is defined as a short polymer of amino acids, of a length typically of 50, 40, 30, 20 or less amino acids.
A “protein” as contemplated herein typically comprises a polymer of naturally occurring amino acids (e.g., alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine). The proteins contemplated herein may be further modified in vitro or in vivo to include non-amino acid moieties. These modifications may include but are not limited to acylation (e.g., O-acylation (esters), N-acylation (amides), S-acylation (thioesters)), acetylation (e.g., the addition of an acetyl group, either at the N-terminus of the protein or at lysine residues), formylation lipoylation (e.g., attachment of a lipoate, a C8 functional group), myristoylation (e.g., attachment of myristate, a C14 saturated acid), palmitoylation (e.g., attachment of palmitate, a C16 saturated acid), alkylation (e.g., the addition of an alkyl group, such as an methyl at a lysine or arginine residue), isoprenylation or prenylation (e.g., the addition of an isoprenoid group such as farnesol or geranylgeraniol), amidation at C-terminus, glycosylation (e.g., the addition of a glycosyl group to either asparagine, hydroxylysine, serine, or threonine, resulting in a glycoprotein). Distinct from glycation, which is regarded as a nonenzymatic attachment of sugars, polysialylation (e.g., the addition of polysialic acid), glypiation (e.g., glycosylphosphatidylinositol (GPI) anchor formation, hydroxylation, iodination (e.g., of thyroid hormones), and phosphorylation (e.g., the addition of a phosphate group, usually to serine, tyrosine, threonine or histidine).
The Cas9 proteins disclosed herein may include “wild type” Cas9 protein and variants, mutants, and derivatives thereof. As used herein the term “wild type” is a term of the art understood by skilled persons and means the typical form of an organism, strain, gene or characteristic as it occurs in nature as distinguished from mutant or variant forms. As used herein, a “variant, “mutant,” or “derivative” refers to a protein molecule having an amino acid sequence that differs from a reference protein or polypeptide molecule. A variant or mutant may have one or more insertions, deletions, or substitutions of an amino acid residue relative to a reference molecule. A variant or mutant may include a fragment of a reference molecule. For example, a Cas9 mutant or variant molecule may one or more insertions, deletions, or substitution of at least one amino acid residue relative to the Cas9 full-length polypeptide. The sequence of the full-length Cas9 protein from Neisseria meningitidis is presented as SEQ ID NO:1 and may be used as a reference in this regard.
Regarding proteins, a “deletion” refers to a change in the amino acid sequence that results in the absence of one or more amino acid residues. A deletion may remove at least 1, 2, 3, 4, 5, 10, 20, 50, 100, 200, or more amino acids residues. A deletion may include an internal deletion and/or a terminal deletion (e.g., an N-terminal truncation, a C-terminal truncation or both of a reference polypeptide).
Regarding proteins, “fragment” is a portion of an amino acid sequence which is identical in sequence to but shorter in length than a reference sequence. A fragment may comprise up to the entire length of the reference sequence, minus at least one amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous amino acid residues of a reference polypeptide, respectively. In some embodiments, a fragment may comprise at least 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 150, 250, or 500 contiguous amino acid residues of a reference polypeptide. Fragments may be preferentially selected from certain regions of a molecule. The term “at least a fragment” encompasses the full length polypeptide. A fragment of a Cas9 protein may comprise or consist essentially of a contiguous portion of an amino acid sequence of the full-length Cas9 protein (SEQ ID NO:1). A fragment may include an N-terminal truncation, a C-terminal truncation, or both truncations relative to the full-length Cas9 protein.
Regarding proteins, the words “insertion” and “addition” refer to changes in an amino acid sequence resulting in the addition of one or more amino acid residues. An insertion or addition may refer to 1, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, or more amino acid residues. A variant of a Cas9 protein may have N-terminal insertions, C-terminal insertions, internal insertions, or any combination of N-terminal insertions, C-terminal insertions, and internal insertions.
Regarding proteins, the phrases “percent identity” and “% identity,” refer to the percentage of residue matches between at least two amino acid sequences aligned using a standardized algorithm. Methods of amino acid sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail below, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide. Percent identity for amino acid sequences may be determined as understood in the art. (See, e.g., U.S. Pat. No. 7,396,664, which is incorporated herein by reference in its entirety). A suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST), which is available from several sources, including the NCBI, Bethesda, Md., at its website. The BLAST software suite includes various sequence analysis programs including “blastp,” that is used to align a known amino acid sequence with other amino acids sequences from a variety of databases. As described herein, variants, mutants, or fragments (e.g., a Cas9 protein variant, mutant, or fragment thereof) may have 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 80%, 70%, 60%, or 50% amino acid sequence identity relative to a reference molecule (e.g., relative to the Cas9 full-length polypeptide (SEQ ID:1)).
Regarding proteins, percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.
Regarding proteins, the amino acid sequences of variants, mutants, or derivatives as contemplated herein may include conservative amino acid substitutions relative to a reference amino acid sequence. For example, a variant, mutant, or derivative protein may include conservative amino acid substitutions relative to a reference molecule. “Conservative amino acid substitutions” are those substitutions that are a substitution of an amino acid for a different amino acid where the substitution is predicted to interfere least with the properties of the reference polypeptide. In other words, conservative amino acid substitutions substantially conserve the structure and the function of the reference polypeptide. The following table provides a list of exemplary conservative amino acid substitutions which are contemplated herein:
Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.
The disclosed proteins, mutants, variants, or described herein may have one or more functional or biological activities exhibited by a reference polypeptide (e.g., one or more functional or biological activities exhibited by wild-type Cas9 protein). For example, the disclosed Cas9 proteins, mutants, variants, or derivatives thereof may have one or more biological activities that include: binding to a single-stranded RNA, binding to a double-stranded RNA, binding to a target polynucleotide sequence, nicking a single strand of the target DNA sequence, and/or cleaving both strands of the target DNA sequence.
The disclosed Cas9 proteins may be substantially isolated or purified. The term “substantially isolated or purified” refers to amino acid sequences that are removed from their natural environment, and are at least 60% free, preferably at least 75% free, and more preferably at least 90% free, even more preferably at least 95% free from other components with which they are naturally associated.
Also disclosed herein are polynucleotides, for example polynucleotide sequences that encode Cas9 proteins (e.g., DNA that encodes a polypeptide having the amino acid sequence of SEQ ID NO:1 or a polypeptide variant having an amino acid sequence with at least about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:1; DNA comprising the polynucleotide sequence of SEQ ID NO:2; DNA comprising the polynucleotide sequence of SEQ ID NO:3; or Cas9 mRNA). Other polynucleotides contemplate herein are RNAs that direct Cas9-mediated binding, nicking, and/or cleaving of a target DNA sequence (e.g., tracrRNA, crRNA, sgRNA) and DNA that encodes such RNAs. The terms “polynucleotide,” “polynucleotide sequence,” “nucleic acid” and “nucleic acid sequence” refer to a nucleotide, oligonucleotide, polynucleotide (which terms may be used interchangeably), or any fragment thereof. These phrases also refer to DNA or RNA of genomic, natural, or synthetic origin (which may be single-stranded or double-stranded and may represent the sense or the antisense strand).
Regarding polynucleotide sequences, the terms “percent identity” and “% identity” refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences. Percent identity for a nucleic acid sequence may be determined as understood in the art. (See, e.g., U.S. Pat. No. 7,396,664, which is incorporated herein by reference in its entirety). A suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST), which is available from several sources, including the NCBI, Bethesda, Md., at its website. The BLAST software suite includes various sequence analysis programs including “blastn,” that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called “BLAST 2 Sequences” that is used for direct pairwise comparison of two nucleotide sequences. “BLAST 2 Sequences” can be accessed and used interactively at the NCBI website. The “BLAST 2 Sequences” tool can be used for both blastn and blastp (discussed above).
Regarding polynucleotide sequences, percent identity may be measured over the length of an entire defined polynucleotide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.
Regarding polynucleotide sequences, “variant,” “mutant,” or “derivative” may be defined as a nucleic acid sequence having at least 50% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the “BLAST 2 Sequences” tool available at the National Center for Biotechnology Information's website. (See Tatiana A. Tatusova, Thomas L. Madden (1999), “Blast 2 sequences—a new tool for comparing protein and nucleotide sequences”, FEMS Microbiol Lett. 174:247-250). Such a pair of nucleic acids may show, for example, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length.
Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code where multiple codons may encode for a single amino acid. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein. For example, polynucleotide sequences as contemplated herein may encode a Cas9 protein and may be codon-optimized for expression in a particular host. In the art, codon usage frequency tables have been prepared for a number of host organisms including humans, mouse, rat, pig, E. coli, plants, and other host cells.
A “recombinant nucleic acid” is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques known in the art. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.
“Substantially isolated or purified” nucleic acid or amino acid sequences are contemplated herein. The term “substantially isolated or purified” refers to nucleic acid or amino acid sequences that are removed from their natural environment, and are at least 60% free, preferably at least 75% free, and more preferably at least 90% free, even more preferably at least 95% free from other components with which they are naturally associated.
“Transformation” or “transfected” describes a process by which exogenous nucleic acid (e.g., DNA or RNA) is introduced into a recipient cell. Transformation or transfection may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation or transfection is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment.
Methods of non-viral delivery of nucleic acids include lipofection, nucleofection, microinjection, electroporation, biolistics, virosomes, liposomes, immunoliposomes, polycation or lipid:nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA. Lipofection is described in e.g., U.S. Pat. Nos. 5,049,386, 4,946,787; and 4,897,355) and lipofection reagents are sold commercially (e.g., Transfectam™ and Lipofectin™). Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides include those of Felgner, WO 91/17424; WO 91/16024. Delivery can be to cells (e.g. in vitro or ex vivo administration) or target tissues (e.g. in vivo administration). The term “transformed cells” or “transfected cells” includes stably transformed or transfected cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed or transfected cells which express the inserted DNA or RNA for limited periods of time.
The polynucleotide sequences contemplated herein may be present in expression vectors. For example, the vectors may comprise: (a) a polynucleotide encoding an ORF of a Cas9 protein; (b) a polynucleotide that expresses an RNA that directs Cas9-mediated binding, nicking, and/or cleaving of a target DNA sequence; and both (a) and (b). The polynucleotide present in the vector may be operably linked to a prokaryotic or eukaryotic promoter. “Operably linked” refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame. Vectors contemplated herein may comprise a heterologous promoter (e.g., a eukaryotic or prokaryotic promoter) operably linked to a polynucleotide that encodes a Cas9 protein. A “heterologous promoter” refers to a promoter that is not the native or endogenous promoter for the protein or RNA that is being expressed. For example, a heterologous promoter for a Cas9 protein of Neisseria menigitidis may include a eukaryotic promoter or a prokaryotic promoter that is not the native, endogenous promoter for the Cas9 protein of Neisseria menigitidis.
As used herein, “expression” refers to the process by which a polynucleotide is transcribed from a DNA template (such as into and mRNA or other RNA transcript) and/or the process by which a transcribed mRNA is subsequently translated into peptides, polypeptides, or proteins. Transcripts and encoded polypeptides may be collectively referred to as “gene product.” If the polynucleotide is derived from genomic DNA, expression may include splicing of the mRNA in a eukaryotic cell.
The term “vector” refers to some means by which nucleic acid (e.g., DNA) can be introduced into a host organism or host tissue. There are various types of vectors including plasmid vector, bacteriophage vectors, cosmid vectors, bacterial vectors, and viral vectors. As used herein, a “vector” may refers to a recombinant nucleic acid that has been engineered to express a heterologous polypeptide (e.g., a Cas9 protein). The recombinant nucleic acid typically includes cis-acting elements for expression of the heterologous polypeptide.
Any of the conventional vectors used for expression in eukaryotic cells may be used for directly introducing DNA into a subject. Expression vectors containing regulatory elements from eukaryotic viruses may be used in eukaryotic expression vectors (e.g., vectors containing SV40, CMV, or retroviral promoters or enhancers). Exemplary vectors include those that express proteins under the direction of such promoters as the SV40 early promoter, SV40 later promoter, metallothionein promoter, human cytomegalovirus promoter, murine mammary tumor virus promoter, and Rous sarcoma virus promoter. Expression vectors as contemplated herein may include prokaryotic control sequences that modulate expression of a heterologous protein (e.g. Cas9 protein. Prokaryotic expression control sequences may include constitutive or inducible promoters (e.g., T3, T7, Lac, trp, or phoA), ribosome binding sites, or transcription terminators.
The vectors contemplated herein may be introduced and propagated in a prokaryote, which may be used to amplify copies of a vector to be introduced into a eukaryotic cell or as an intermediate vector in the production of a vector to be introduced into a eukaryotic cell (e.g. amplifying a plasmid as part of a viral vector packaging system). A prokaryote may be used to amplify copies of a vector and express one or more nucleic acids, such as to provide a source of one or more proteins for delivery to a host cell or host organism. Expression of proteins in prokaryotes may be performed using Escherichia coli with vectors containing constitutive or inducible promoters directing the expression of either a Cas9 protein or a fusion protein comprising a Cas9 protein or a fragment thereof. Fusion vectors add a number of amino acids to a protein encoded therein, such as to the amino terminus of the recombinant protein. Such fusion vectors may serve one or more purposes, such as: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification (e.g., a His tag); (iv) to tag the recombinant protein for identification (e.g., such as Green fluorescence protein (GFP) or an antigen (e.g., an HA tag such as SEQ ID NOs:6 and 7) that can be recognized by a labelled antibody); (v) to promote localization of the recombinant protein to a specific area of the cell (e.g., where the Cas9 protein is fused (e.g., at its N-terminus or C-terminus) to a nuclear localization signal (NLS) which may include the NLS of SV40 (e.g., SEQ ID NOs:4 and 5, which is a monopartite NLS), nucleoplasmin (which comprises a bipartite signal of two clusters of basic amino acids separated by a spacer of about 10 amino acids), C-myc, M9 domain of hnRNP A1, or a synthetic NLS (e.g., SEQ ID NOs:8 and 9)). The importance of neutral and acidic amino acids in NLS have been studied. (See Makkerh et al. (1996) Curr Biol 6(8):1025-1027). Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase.
The presently disclosed methods may include delivering one or more polynucleotides, such as or one or more vectors as described herein, one or more transcripts thereof, and/or one or proteins transcribed therefrom, to a host cell. Further contemplated are host cells produced by such methods, and organisms (such as animals, plants, or fungi) comprising or produced from such cells. In some embodiments, a CRISPR enzyme (e.g., Cas9 protein) in combination with (and optionally complexed with) a guide sequence is delivered to a cell. Conventional viral and non-viral based gene transfer methods can be used to introduce nucleic acids in mammalian cells or target tissues. Such methods can be used to administer nucleic acids encoding components of a CRISPR system to cells in culture, or in a host organism. Non-viral vector delivery systems include DNA plasmids, RNA (e.g. a transcript of a vector described herein), naked nucleic acid, and nucleic acid complexed with a delivery vehicle, such as a liposome. Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell.
In the methods contemplated herein, a host cell may be transiently or non-transiently transfected (i.e., stably transfected) with one or more vectors described herein. In some embodiments, a cell is transfected as it naturally occurs in a subject (i.e., in situ). In some embodiments, a cell that is transfected is taken from a subject (i.e., explanted). In some embodiments, the cell is derived from cells taken from a subject, such as a cell line. Suitable cells may include stem cells (e.g., embryonic stem cells and pluripotent stem cells). A cell transfected with one or more vectors described herein may be used to establish a new cell line comprising one or more vector-derived sequences. In the methods contemplated herein, a cell may be transiently transfected with the components of a CRISPR system as described herein (such as by transient transfection of one or more vectors, or transfection with RNA), and modified through the activity of a CRISPR complex, in order to establish a new cell line comprising cells containing the modification but lacking any other exogenous sequence.
The methods, vectors, and systems described herein may be used to produce a non-human transgenic animal or a transgenic plant or algae. Transgenic animals may include a mammal, such as a mouse, rat, or rabbit. Methods for producing transgenic plants and animals are known in the art, and generally begin with a method of cell transfection with one or more vectors as contemplated herein.
The following Examples are illustrative and are not intended to limit the scope of the claimed subject matter.
Reference is made to Zhang et al., “Processing-Independent CRISPR RNAs Limit Natural Transformation in Neisseria meningitidis” Molecular Cell 50, 488-503, May 23, 2013, the contents of which are incorporated herein by reference.
Abstract
CRISPR interference confers adaptive, sequence-based immunity against viruses and plasmids and is specified by CRISPR RNAs (crRNAs) that are transcribed and processed from spacer-repeat units. Pre-crRNA processing is essential for CRISPR interference in all systems studied thus far. Here, our studies of crRNA biogenesis and CRISPR interference in naturally competent Neisseria spp. reveal a unique crRNA maturation pathway in which crRNAs are transcribed from promoters that are embedded within each repeat, yielding crRNA 5′ ends formed by transcription and not by processing. Although crRNA 3′ end formation involves RNase III and trans-encoded tracrRNA, as in other Type II CRISPR systems, this processing is dispensable for interference. The meningococcal pathway is the most streamlined CRISPR/cas system characterized to date. Endogenous CRISPR spacers limit natural transformation, which is the primary source of genetic variation that contributes to immune evasion, antibiotic resistance, and virulence in the human pathogen N. meningitidis. Highlights of these new CRISPRS include the following: unlike previously described CRISPRs, each Neisseria repeat carries its own promoter; pre-crRNA processing is dispensable for CRISPR interference in Neisseria spp; CRISPR interference blocks natural transformation in the pathogen N. meningitides; and Neisseria CRISPR/Cas systems are the most streamlined observed to date
Introduction
Clustered, regularly interspaced, short palindromic repeat (CRISPR) loci confer sequence-based, adaptive immunity against virus infection and plasmid conjugation in bacteria and archaea (Haft et al., 2005; Makarova et al., 2006; Barrangou et al., 2007; Terns and Terns, 2011; Wiedenheft et al., 2012). CRISPRs consist of short repeats separated by similarly sized, non-repetitive sequences called spacers, which are derived from previously encountered invasive sequences such as viral genomes or plasmids (Bolotin et al., 2005; Mojica et al., 2005; Pourcel et al., 2005). CRISPR loci are transcribed as long CRISPR RNA (crRNA) precursors that are processed into small crRNAs (Brouns et al., 2008; Hale et al., 2008). Pre-crRNA transcription is generally driven by promoters within “leader” sequences outside of the CRISPR array. The crRNAs assemble with CRISPR-associated (Cas) proteins into complexes that cleave complementary “protospacer” sequences within invasive nucleic acids, a phenomenon known as CRISPR interference (Karginov and Hannon, 2010; Marraffini and Sontheimer, 2010; Terns and Terns, 2011; Wiedenheft et al., 2012). The sequence information in crRNAs is used to guide Cas complexes to their targets on viruses and plasmids, leading to their destruction (Barrangou et al., 2007; Brouns et al., 2008; Marraffini and Sontheimer, 2008; Hale et al., 2009; Garneau et al., 2010; Westra et al., 2012). Most CRISPR/Cas systems cleave incoming DNAs (Marraffini and Sontheimer, 2008; Garneau et al., 2010; Westra et al., 2012), though RNA-cleaving systems have also been identified (Hale et al., 2009, 2012; Zhang et al., 2012).
CRISPR/Cas systems have been classified into types I, II and III based primarily on their cas gene complement (Makarova et al., 2011a). Common to all of these three types is that the CRISPR array is transcribed as a multimeric pre-crRNA that is processed into crRNAs that each contain an individual spacer flanked on one or both sides by partial repeat sequences (Bhaya et al., 2011). However, the molecular events underlying processing dramatically differ. Whereas in Type I and III systems the processing enzymes are encoded within the CRISPR/cas locus, Type II systems use the host enzyme RNase III (encoded by the rnc gene) and a noncoding RNA called tracrRNA (Deltcheva et al., 2011). In Streptococcus pyogenes SF370, an rnc mutant abolishes the function of a Type II CRISPR/cas locus, indicating that pre-crRNA processing is essential (Deltcheva et al., 2011).
The importance of the Type II CRISPR/Cas pathway has been dramatically enhanced by its development into a system for RNA-guided DNA cleavage in vitro (Jinek et al., 2012) and genome editing in vivo (Jinek et al., 2013; Cho et al., 2013; Cong et al., 2013; DiCarlo et al., 2013; Hwang et al., 2013; Jiang et al., 2013; Mali et al., 2013). Our ability to exploit this new technology further will depend on a deeper understanding of the underlying molecular mechanisms, and will be increased by the characterization of systems that are as simplified and streamlined as possible. Type II CRISPR/Cas loci, which are found in bacteria but not archaea, usually contain four cas genes: cas1, cas2, cas9, and either csn2 (subtype II-A) or cas4 (subtype II-B) (Makarova et al., 2011b). Cas9 is the effector protein for the interference function of existing spacer sequences in the CRISPR array (Sapranauskas et al., 2011; Gasiunas et al., 2012; Jinek et al., 2012), whereas the other proteins are thought to be involved in the acquisition of new CRISPR spacers. The tracrRNA is essential for crRNA-directed DNA recognition and Cas9-catalyzed DNA cleavage in vitro, even with crRNAs that bypass processing (Jinek et al., 2012). DNA targeting in both Type I and Type II systems requires not only crRNA/target complementarity but also a protospacer adjacent motif (PAM), which is a short (2-5 nt), conserved sequence just outside of the protospacer (Deveau et al., 2008; Horvath et al., 2008; Mojica et al., 2009; Semenova et al., 2011; Sashital et al., 2012).
Although CRISPR interference was originally defined as a phage defense pathway, CRISPR/Cas systems are now understood to play a broader role in limiting horizontal gene transfer (HGT) (Marraffini and Sontheimer, 2008). The three primary routes of HGT are transformation, conjugation, and phage transduction, and the latter two are well established as being subject to interference by naturally occurring spacers. Artificial means of transformation (e.g. electroporation) can also be blocked by CRISPR interference (Marraffini and Sontheimer, 2008; Deltcheva et al., 2011; Sapranauskas et al., 2011; Semenova et al., 2011), though natural transformation uses a very different DNA uptake process (Chen et al., 2005). An engineered spacer can prevent natural transformation specified by an S. pyogenes CRISPR/cas locus transplanted into Streptococcus pneumonia (Bikard et al., 2012). However, although this artificial system suggests that natural CRISPR/Cas contexts may do likewise, the fundamental question of whether native CRISPR/Cas systems play a role in natural transformation remains to be addressed.
Strains from the genus Neisseria serve as paradigms for natural transformation, as they are competent during all phases of their life cycle and use this process for frequent genetic exchange (Hamilton and Dillard, 2006). Although functional CRISPR/cas systems have not been identified in Neisseria gonorrhoeae, some strains of Neisseria lactamica and Neisseria meningitidis carry apparent Type II CRISPR/cas loci (Grissa et al., 2007). Meningococci are obligate human commensals that can invade the bloodstream and cerebrospinal fluid (Bratcher et al., 2012), and meningococcal disease is responsible for tens of thousands of deaths per year (Stephens et al., 2007).
Here we characterize the CRISPR pathway in neisseriae and find that it exhibits several unique features, most notably a streamlined functional architecture that includes a previously unknown, processing-independent mode of crRNA biogenesis. Furthermore, naturally occurring spacers match sequences from other Neisseria genomes, including a prophage-like meningococcal disease-associated (MDA) island that correlates with invasiveness and pathogenicity (Bille et al., 2005, 2008). We find that a native meningococcal CRISPR/cas locus prevents natural transformation of spacer-matched sequences, suggesting that it can limit the horizontal spread of virulence genes.
Results
dRNA-seq reveals that each repeat in the Neisseria CRISPR carries its own promoter. We analysed all 19 sequenced Neisseria genomes available in the NCBI database (fifteen from N. meningitidis, three from N. gonorrhoeae, and one from N. lactamica) using CRISPRFinder (Grissa et al., 2007) or CRISPRi (Rousseau et al., 2009). We identified seven putative Type II CRISPR/cas loci: six in N. meningitidis strains, and one in N. lactamica 020-06. All were highly similar, and unlike other Type II loci characterized previously (Barrangou et al., 2007; Deltcheva et al., 2011; Magadán et al., 2012), included a set of only three predicted protein-coding genes (cas9, cas1 and cas2) but neither csn2 nor cas4. To examine the expression status of a representative locus, we performed our recently developed dRNA-seq approach (Sharma et al., 2010) on N. lactamica 020-06. We prepared two cDNA libraries from total RNA using a strategy that allows us to distinguish between transcripts with either primary or processed 5′ ends: one library is generated from untreated RNA, whereas the other is treated with terminator exonuclease (TEX), which specifically degrades RNAs with 5′-monophosphate ends (including the abundant rRNAs and tRNAs) that are formed by processing. Primary transcripts with 5′-triphosphate ends survive TEX treatment, resulting in their relative enrichment in the TEX+library.
Our global mapping of cDNA reads identified a tracrRNA and small crRNAs as highly abundant classes of transcripts (
crRNA biogenesis in Neisseria lactamica depends On single promoter elements in each CRISPR repeat. The dRNA-seq results and −10 box similarity suggest that in N. lactamica 020-06, each CRISPR repeat carries its own minimal promoter, and that pre-crRNA transcription initiates independently within each spacer. As an initial test of this hypothesis, we designed a series of transcriptional green fluorescent protein (gfp) fusion constructs containing either single or multiple CRISPR repeats, introduced these constructs into E. coli, and analysed cellular GFP fluorescence. As shown in
To obtain additional proof that each N. lactamica CRISPR repeat carries its own promoter element, we used purified E. coli σ70 RNA polymerase (RNAP) holoenzyme in in vitro transcription assays with linear DNA templates containing either a wild-type or a mutant repeat. A transcript of the expected length (168 nt) was obtained with the wild-type CRISPR repeat template (and with a control −10/−35 promoter construct), but not with the mutated repeat (
RNase III is involved in 3′ end formation of Neisseria crRNAs. The observation that crRNA 5′ ends correspond to sites of transcription initiation in N. lactamica suggests a reduced dependence on processing relative to other CRISPR systems. To determine whether this reduced dependence extends to crRNA 3′ end formation as well or if 3′ processing still occurs, and to extend our studies to other Neisseria strains, we deleted the rnc gene (which encodes RNase III) in N. meningitidis WUE2594, and then compared the tracrRNA and crRNA populations from this Δrnc mutant with wild-type bacteria by northern analysis. As shown in
Repeat/spacer organization and potential targets of Neisseria Type II-C CRISPR loci. Having defined unique features of CRISPR/Cas systems in neisseriae, we turned our attention towards functional analyses, beginning with an examination of CRISPR organization and spacer content. Of the 103 spacers found in the seven CRISPR-positive genomes (
BLASTN searches with the 83 unique spacer sequences for similar sequences in the NCBI database allowed us to identify at least one potential target for 35 (˜42%) of them. For simplicity we required either a perfect match, or at most a single mismatch in the 10 protospacer nucleotides furthest from the PAM (i.e., well outside of the presumptive “seed” sequence that requires perfect complementarity for interference) (Sapranauskas et al., 2011; Semenova et al., 2011; Wiedenheft et al., 2011; Jinek et al., 2012).
CRISPR interference blocks natural transformation in N. meningitides. The preponderance of protospacers in Neisseria spp. genomes suggests that the CRISPR/cas loci could interfere with natural transformation. For our functional analyses addressing this possibility, we focused on N. meningitidis 8013, primarily because it exhibits the most robust transformation competence in our hands. For transformation assays we used the vector pGCC2, which contains an erythromycin resistance gene (ermC) and polylinker inserted into sequences from the gonococcal lctP/aspC locus (
To examine targeting requirements further, we generated a series of mutations in the protospacer or flanking sequences of the pGCC2-derived plasmid targeted by spacer 9 (
Genetic analysis of the N. meningitidis CRISPR/cas locus. In other Type II CRISPR/Cas systems, Cas9 is the only Cas protein that is necessary for interference specified by existing spacers (Barrangou et al., 2007; Deltcheva et al., 2011; Sapranauskas et al., 2011; Jinek et al., 2012). To investigate if Type II-C CRISPR/Cas systems exhibit the same Cas protein requirements, we introduced transposon insertion mutations in the three cas genes—cas1, cas2, and cas9—in N. meningitidis 8013 (
Previous studies of cas9 orthologs from S. thermophilus and S. pyogenes identified two distinct active sites in RuvC-like and HNH nuclease motifs that are important for Cas9 function in vivo and in vitro (Sapranauskas et al., 2011; Gasiunas et al., 2012; Jinek et al., 2012). We engineered alanine mutants in corresponding catalytic residues (D16 in the RuvC domain and H588 in the HNH domain) and tested the abilities of both single mutants to complement the interference defect of the cas9::Tn mutant. Both alanine mutants failed to restore interference (
RNase III-catalysed pre-crRNA processing is dispensable for Type II-C CRISPR interference. Two additional loci—tracrRNA and rnc (the gene encoding RNase III)—have been shown to be essential for crRNA processing and interference in the Type II-A system of S. pyogenes SF370 (Deltcheva et al., 2011). The unique Neisseria biogenesis pathway described above, in which repeat-driven promoters yield crRNAs with unprocessed 5′ ends, raises questions about the roles of tracrRNA and RNase III in this Type II-C system. To examine this issue, we generated N. meningitidis 8013 derivatives carrying a transposon-induced allele of rnc, or a complete deletion of either rnc or tracrRNA (
Intriguingly, despite the previously demonstrated importance of the tracrRNA as a guide for RNase III-mediated processing, we detected no interference defect in either the rnc::Tn or Δrnc mutants (
CRISPR interference limits transformation by Neisseria genomic DNA. Plasmids are rare in N. meningitidis (van Passel et al., 2006), and Neisseria genomic DNA (gDNA) is thought to be the most frequent substrate for natural transformation (Hamilton and Dillard, 2006). To test whether our results with E. coli-isolated plasmids extend to Neisseria gDNA, we generated strains carrying a selectable marker tightly linked to a validated target (protospacer 25). We used the cas9::Tn strain to enable transformation and integration of both empty pGCC2 (
The potential target spectrum of Neisseria CRISPR loci. In silico target analysis for N. meningitidis 8013 CRISPR spacers is summarized in
We also performed in silico target analyses in a more prophage-directed way: we examined the available literature for reported Neisseria prophage and mobile element sequences (Masignani et al., 2001; Braid et al., 2004; Bille et al., 2005; Kawai et al., 2005; Skaar et al., 2005; Joseph et al., 2011) and then searched them for matches to any of the 325 Neisseria protospacers. Overall, among all the 35 unique Neisseria spacers with potential targets, 63% (22/35) match a phage-related protospacer by this criterion (Table 4). We noted that apparent prophage targeting by the N. meningitidis WUE2594 CRISPR is particularly extensive, accounting for 69% (36/52) of all the phage-related potential matches shown in Table 4. We speculate that the presence of a functional Type II-C CRISPR/Cas system with a dozen prophage-matched spacers has contributed to the lack of Nf prophages in the N. meningitidis WUE2594 genome (Joseph et al., 2011 and our observations). The genes most frequently matched (67 out of the 325 protospacers) by Neisseria spacers are those encoding homologues of PivNG/PivNM/irg putative transposases and recombinases (Kawai et al., 2005; Skaar et al., 2005) The fact that these genes are usually adjacent to and probably functionally associated with putative Nf prophage and insertion sequences (Skaar et al., 2005; Kawai et al., 2006) suggests that Neisseria Type II-C CRISPR/Cas system interferes with the acquisition of Nf prophages by targeting their PivNG/PivNM/irg transposase-encoding loci.
We also observed that the candidate phage-related CRISPR targets almost exclusively belong to filamentous prophages (Table 4), including the 8kb MDA (Meningococcal Disease Associated) island associated with invasiveness and pathogenicity (Bille et al., 2005). In contrast, several Mu-like prophages (Masignani et al., 2001; Braid et al., 2004; Joseph et al., 2011) from Neisseria genomes had no CRISPR spacer matches (Table 4). The reasons for the difference in apparent CRISPR targeting of filamentous and Mu-like prophages are not known.
Discussion
CRISPR interference and the third major pillar of horizontal gene transfer. CRISPR/Cas pathways have been revealed as RNA-directed immune systems that protect bacteria and archaea from phage infection and HGT (Karginov and Hannon, 2010; Marraffini and Sontheimer, 2010; Terns and Terns, 2011; Wiedenheft et al., 2012). Several dozen bacterial species are known to be competent for HGT via natural transformation. Of this subset of bacteria, Neisseria spp. are unusual in that their transformation competence is constitutive (Hamilton and Dillard, 2006). Only a few phages are known to infect N. meningitidis, and although conjugative plasmids are present in some meningococcal isolates (van Passel et al., 2006), transformation is the major mechanism for mobilization of meningococcal chromosomal loci (Moxon and Jansen, 2005). Neisseria genomic sequences are preferred substrates for natural transformation, given that DNA uptake is strongly promoted by a short DNA uptake sequence (DUS) that is highly overrepresented in Neisseria spp. chromosomes (Budroni et al., 2011). DNA exchange is so frequent that the population structures of most neisseriae are effectively panmictic, with little propensity for the emergence of clonal subpopulations (Smith et al., 1993). Frequent HGT in N. meningitidis is thought to promote capsule switching and other forms of antigenic variation, homology-based DNA repair, and other functions (Hamilton and Dillard, 2006). Native CRISPR/Cas systems have previously been shown to prevent phage infection (and, by inference, phage transduction) and conjugation, which constitute two of the primary routes of HGT. Our results reveal a role for a native CRISPR/Cas system in preventing the third main route of HGT, natural transformation. This is consistent with recent reports that CRISPR/Cas systems can target loci that are already established in bacterial or archaeal chromosomes (Edgar and Qimron, 2010; Gudbergsdottir et al., 2011; Jiang et al., 2013), indicating that interference does not depend on the invasive DNA's route of entry. Similarly, an engineered, heterologous CRISPR/Cas system introduced into Streptococcus pneumoniae can block natural transformation during active infection in mice (Bikard et al., 2012). We find that a native CRISPR/Cas system in N. meningitidis can block the transformation events that can be so important for immune evasion and other critical aspects of invasiveness and pathogenicity. Intriguingly, the ability of native CRISPR systems to block natural transformation would be expected to enable the selection of spacers that discriminate against specific chromosomal loci that negatively affect the fitness of certain strains or under certain conditions.
Although relatively few phages are known to infect N. meningitidis, they are not unknown (Kawai et al., 2005). Several genomic islands have been identified that resemble phages and could therefore represent prophage sequences (Bille et al., 2005, 2008; Joseph et al., 2011). One such sequence, the MDA island, correlates with invasiveness and pathogenicity in young adults (Bille et al., 2005, 2008). The existence of numerous CRISPR spacers with the potential to target these sequences suggests that CRISPR interference plays a role in shaping prophage content and serves phage defense functions in N. meningitidis, as elsewhere. CRISPR interference could limit the spread of prophages via either transformation or infection. Accordingly, CRISPR interference could negatively correlate with meningococcal pathogenicity, as suggested in enterococci (Palmer and Gilmore, 2010) and streptococci (Bikard et al., 2012). Alternatively, meningococcal Cas9 could participate in other regulatory events that contribute to pathogenicity, as suggested very recently (Sampson et al., 2013).
It is noteworthy that many N. meningitidis and N. lactamica strains encode CRISPR systems, while strains of the closely related N. gonorrhoeae with clearly functional CRISPR systems have not been identified. It is believed that these organisms split in relatively recent times (<100,000 years ago), evolutionarily speaking, but exact estimates have been stymied by the large recombination frequencies in these species (Bennett et al., 2010). It is equally possible that the nasopharyngeal-localized species gained the system after the split, or that N. gonorrhoeae lost the CRISPR system after the split. Both pathogens have been suggested not to establish long-lasting clones and tend towards linkage equilibrium (Buckee et al., 2008). It may not be coincidental that N. meningitidis carries a CRISPR system and can develop semi-clonal lineages (Bart et al., 2001), given that the CRISPR system could provide a short-term barrier to HGT. It is also possible that the co-existence of commensal Neisseria species such as N. lactamica and N. meningitidis in the nasal pharynx (Feil and Sprat, 2001) selects for a system that limits genetic exchange, and intriguingly, some N. lactamica and N. meningitidis isolates show large amounts of exchange while others show lower signatures of exchange (Hanage et al., 2005; Corander et al., 2012). In contrast, N. gonorrhoeae inhabits a niche that is devoid of other closely related bacteria that encode the DUS to allow efficient transformation of their sequences (Vazques et al., 1993; Cehovin et al., 2013).
Towards a minimal CRISPR/Cas system. In CRISPR/Cas systems investigated to date, crRNAs are transcribed from an external promoter, generating a multimeric precursor. The pre-crRNA is processed by endonucleolytic cleavage to generate mature crRNAs (Carte et al., 2008; Haurwitz et al., 2010; Gesner et al., 2011), and processing is essential for interference in vivo (Brouns et al., 2008; Deltcheva et al., 2011; Hale et al., 2012; Westra et al., 2012). The potential presence of minimal and apparently fortuitous promoter elements has been noted within certain CRISPRs of Sulfolobus solfataricus P2, though they are not thought to account for the functional expression of crRNA and in fact appear to be suppressed by the repeat-binding protein Cbp1 (Deng et al., 2012). The results presented here reveal that streamlined CRISPR/Cas systems exist in which pre-crRNA processing is not essential (
Like other Type II CRISPR/Cas systems, neisseriae produce a tracrRNA that apparently anneals to pre-crRNA and enables binding and cleavage by a RNase III. This reaction generates crRNA 3′ ends, and rnc mutants accumulate multimeric crRNA precursors. However, these rnc mutants exhibit no interference defect, indicating that processing is not essential. In addition, while the tracrRNA is essential for interference, its role in directing processing is not, since processing is itself dispensable. This provides the first clear indication that the tracrRNA is required for post-processing events such as target DNA binding and cleavage in bacterial cells, as it is in vitro (Jinek et al., 2012).
Among the three main types of CRISPR/Cas pathways, the Type II systems are the simplest ones characterized thus far, as judged by the number of components and essential steps. Both Type II-A and Type II-B systems include the CRISPR array itself, a tracrRNA, four protein-coding genes encoded within the cas locus, and the host factor RNase III (Deltcheva et al., 2011; Makarova et al., 2011b; Magadán et al., 2012; Chylinski et al., 2013). The Neisseria systems that we have characterized are even more streamlined: they do not require a separate leader sequence to drive crRNA transcription, they lack one of the four cas/csn genes present in Type II-A or II-B systems, and they do not require RNase III or crRNA processing. The Neisseria systems are among the founding members of a new CRISPR/Cas subtype (Type II-C) that is characterized by a smaller number of cas/csn proteins (Koonin and Makarova, 2013; Chylinski et al., 2013), and in at least some cases by repeat-embedded promoters and processing independence.
Importantly, recent reports have shown that Type II CRISPR/Cas systems can be ported into eukaryotic cells and employed for RNA-directed genome editing and genome binding, including multiplexed applications specified by multiple spacers (Jinek et al., 2012, 2013; Cho et al., 2013; Cong et al., 2013; DiCarlo et al., 2013; Hwang et al., 2013; Mali et al., 2013; Qi et al., 2013). The Cas9 effector proteins from neisseriae share the conserved features observed in the S. pyogenes and S. thermophilus Cas9 enzymes used in these studies (Chylinski et al., 2013). The fewer the functional requirements for the operation of such systems, the greater their versatility and applicability will be. Separately encoded crRNAs and tracrRNAs are more efficient in vivo than single-guide RNAs that combine essential crRNA and tracrRNA domains in the same transcript (Cong et al., 2013). Although endogenous eukaryotic activities can substitute for bacterial RNase III to process tracrRNA/pre-crRNA hybrids in human and mouse cells (Cong et al., 2013), it is not known whether RNase III will be dispensable in other eukaryotic contexts, or indeed in all mammalian cell types. Accordingly, the identification of processing-independent CRISPR/Cas systems could increase the range of applications in eukaryotic genome editing, especially in light of the potential toxicity of bacterial RNase III expression (Pines et al., 1988). Such applications will benefit from further analysis of meningococcal Cas9 activity, including the definition of the presumptive cleavage sites relative to the PAM.
Experimental Procedures
Bacterial Strains, Plasmids, and Oligonucleotides. N. lactamica 020-06, N. meningitidis WUE2594 and 8013, and mutant derivatives thereof that were used in this study are listed in Supplemental Experimental Procedures, as are complete lists of all plasmids and DNA oligonucleotides.
Mutant Strain Construction. All mutants were confirmed by PCR and DNA sequencing. Most mutant strains were generated by transformation with appropriately constructed plasmids. For generation of the cas9, rnc, and control NMV_1851 transposon-induced alleles in the 8013 strain background, we used gDNA from the corresponding mutant in the NeMeSys collection (Rusniok et al., 2009) to transform 8013. For generation of the Δrnc derivative of 8013, we used gDNA from the WUE2594 Δrnc derivative that was initially made by a plasmid-based approach. For complementation of cas9::Tn, Acas9, and ΔtracrRNA mutants, we cloned wildtype copies of the relevant gene into plasmid pGCC2 and transformed the resulting plasmids into the parental mutant strain.
RNA Extraction and Depletion of Processed RNAs. For 020-06, WUE2594 and its mutant derivatives, total RNA was extracted from frozen cell pellet lysates using the hot-phenol method described previously (Blomberg et al., 1990). For depletion of processed transcripts, equal amounts of total RNA were incubated with Terminator™ exonuclease (TEX) (Epicentre) or in buffer alone as described (Sharma et al., 2010). For 8013 and its mutant derivatives, total RNAs were extracted from frozen cell pellets using miRNeasy Mini Kit (Qiagen) with two additional steps: a ten minute initial cell lysis with lysozyme and Proteinase K, and a later on-column DNase digestion step (the RNase-Free DNase Set, Qiagen).
dRNA-seq. Libraries for Solexa sequencing (HiSeq) of cDNA were constructed by vertis Biotechnology AG, Germany (http://www.vertis-biotech.com/), as described previously for eukaryotic microRNA (Berezikov et al., 2006) but omitting the RNA size-fractionation step prior to cDNA synthesis. cDNA libraries were sequenced using a HiSeq 2000 machine (Illumina) in single read mode at the Max Planck Genome Centre Cologne (Cologne, Germany). Data analysis was done as described (Chao et al., 2012), with the only exception being that the minimal read length after trimming and clipping was 12 nt instead of 20 nt.
Transcriptional gfp Fusions. The inserts used for the construction of the transcriptional gfp fusion plasmids were generated with synthetic DNA oligonucleotides. E. coli cells were transformed with these plasmids and grown on agar plates for fluorescence imaging. To measure GFP fluorescence, single colonies were grown in LB broth, fixed, and analyzed by flow cytometry.
In vitro Transcription. Templates for in vitro transcription assays were PCR-generated, gel-purified 210 bp DNA fragments amplified from pNH13, pNH14, or pNH15. Transcription reactions with sigma-saturated E. coli RNA Polymerase holoenzyme (Epicentre) included α-[32 P]-ATP.
Natural Transformation. Natural transformation assays were performed as described (Duffin and Seifert, 2012). Transformation frequencies were reported as antibiotic-resistant cfu/ml divided by total cfu/ml from at least three independent experiments (mean±s.e.m.).
Accession Numbers. The Gene Expression Ominbus (GEO) accession number for the dRNA-Seq data reported in this paper is GSE44582.
Bacterial Strains and Growth Conditions. N. lactamica 020-06, N. meningitidis WUE2594 and 8013, and mutant derivatives thereof that were used in this study are listed below.
N. lactamica 020-06
N. meningitidis WUE2594
N. meningitidis 8013
Strain 8013 and its derivatives were grown on GC Medium Base (GCB) (Difco) plates with appropriate antibiotics and Kellogg's supplements I and II (22.2 mM glucose, 0.68 mM glutamine, 0.45 mM co-carboxylase, 1.23 mM Fe(NO3)3; all from Sigma). Antibiotic concentrations used for 8013 were 2.5 μg/ml for erythromycin; 50 μg/ml for kanamycin; 50 μg/ml for streptomycin; and 2.5 μg/ml for chloramphenicol. 020-06, WUE2594, and derivatives thereof were grown on GC agar (Difco) with PolyViteX (bioMerieux), and with 7 μg/ml chloramphenicol when appropriate. All solid cultures were incubated at 37° C. in a 5% CO2 humidified atmosphere.
Liquid cultures of 020-06, WUE2594 and its derivatives were grown in a 37° C. shaker-incubator at 220 rpm without added CO2. Bacteria grown on Columbia agar plates with 5% sheep blood (bioMerieux) were harvested and a starter culture was inoculated to a final OD600 of 0.4 in a flask containing 10 ml of Proteose Peptone Media (PPM+) medium supplemented with PolyViteX (bioMerieux). After one hour the starter culture was used to inoculate a flask containing 25 ml PPM+/PolyViteX to a final OD600 of 0.05. When the cultures reached mid-log (OD600 0.5) or early stationary (OD600 1.0) phase, 10 ml of culture were harvested. The cell samples were immediately centrifuged for 10 min at 4,000 rpm. The cell pellet was frozen in liquid N2 and stored at −80° C. until RNA extraction.
Mutant Strain Construction. All mutants were confirmed by PCR and DNA sequencing. PCRs for verifying strains or transformants were performed with Taq or OneTaq DNA Polymerases (NEB) using either 10 ng of genomic DNA (25 cycles) or 0.5 μl CLS extracts (35 cycles) as templates. Chromosomal DNAs were isolated using QIAamp DNA Mini Kit (Qiagen).
The cas1 and cast transposon-induced alleles were made by transforming 8013 with the plasmids pCR2.1/cas1-Kan and pCR2.1/cas2-Kan, respectively, followed by KanR selection. For generation of the cas9, rnc, and control NMV_1851 transposon-induced alleles in the 8013 strain background, we used chromosomal DNA from the corresponding mutant in the NeMeSys collection (Rusniok et al., 2009) to transform 8013, and then selected KanR transformants. The cas9::Tn mutant strain with a transposon insertion after the 604th nucleotide of the ORF was constructed with NeMeSys mutant 23/6. The rnc::Tn mutant strain with a transposon insertion after 574th nucleotide of the ORF was constructed with NeMeSys mutant 6/47. A control strain with a transposon insertion after the 22nd ORF nucleotide of gene NMV_1851 (which encodes a hypothetical protein) was constructed using NeMeSys mutant 73/5. The kan-marked ΔtracrRNA strain was made by transforming 8013 with plasmid pSMARTHCamp/Δtracr+Kan, followed by KanR selection.
The WUE2594 Δrnc derivative was constructed by replacing the rnc gene with a kanamycin resistance cassette. WUE2594 was then transformed with the plasmid pBJ1 and KanR colonies were selected. The Δrnc derivative of 8013 was made by transforming 8013 with genomic DNA from the WUE2594 Δrnc derivative, followed by KanR selection.
To create the unmarked, in-frame Δcas9 allele (removing all ORF nts except for the five N-terminal and five C-terminal codons), we first selected a spontaneous streptomycin-resistant (SmR) mutant of 8013 by plating 3×109 wt cells on GCB plates with 50 μg/ml streptomycin, and selecting an SmR colony. We confirmed that it carried an A128G substitution in rpsL, resulting in a K34R missense mutation. We then transformed this SmR derivative with plasmid pSTblue-1/Δcas9/CAT-rpsL, in which a dual-marker cassette [CAT (chloramphenicol acetyltransferase) and wild-type rpsL] replaced most of the cas9 ORF. The resulting CmR transformants are also streptomycin-sensitive (SmS), since the SmS phenotype conferred by the wildtype rpsL is dominant over the SmR phenotype conferred by the rpsLA128G allele at the native locus. SmS CmR transformants were then transformed with plasmid pSTblue-1/Δcas9. SmR CmS colonies from this transformation were screened by PCR to confirm replacement of the dual marker cassette with the unmarked cas9 deletion.
For complementation of cas9::Tn, Δcas9, and ΔtracrRNA mutants, we cloned wildtype copies of the relevant gene into plasmid pGCC2, transformed the resulting plasmids into the parental mutant strain, and selected erythromycin-resistant (ErmR) transformants.
To generate strains carrying a selectable marker tightly linked to a target protospacer (as a source of chromosomal DNA for genomic transformation experiments), plasmids pGCC2 or pGCC2-MC8013spacer25 were transformed into the cas9::Tn strain, and ErmR transformants were selected. Similarly, pYZEJS040 or pYZEJS040-MC8013spacer25 were transformed into the cas9::Tn strain, and CmR transformants were selected.
Plasmids. A complete list of all plasmids, as well as information on their construction, is provided at the end of this section. E. coli Top10 cells (Invitrogen) were used for all cloning procedures. All plasmid constructions were sequence-verified. PCR reactions for cloning were performed with Platinum Pfx DNA Polymerase (Invitrogen).
The inserts used for the construction of transcriptional gfp fusion plasmids pNH13, pNH14, pNH15 and pNH18 were generated by duplex formation of complementary DNA oligonucleotides. Oligonucleotide pairs were JVO9535/JVO9536 and JVO9537/JVO9538 for Neisseria spp. wildtype (pNH13) and mutant (pNH14) CRISPR repeat constructs, respectively; JVO9599/JVO9601 for the wildtype CRISPR repeat from Campylobacter jejunii NCTC11168 (pNH18); and JVO9539/JVO9540 for the −10/−35 positive control promoter from T7A1 phage (pNH15). For each DNA duplex insert, 100 nM sense oligonucleotides were annealed with equimolar amounts of antisense oligonucleotides at 95° C. for 3 min, followed by slow cooling to room temperature. DNA duplexes were digested with Aatll/Nhel and cloned into AatII/NheI-digested pAS093. For construction of 3×CRISPR-repeat-spacer unit-gfp transcriptional fusion plasmid pNH17, the plasmid pAS093 was digested with AatII/NheI and ligated to AatII/NheI-digested PCR products amplified from N. lactamica 020-06 chromosomal DNA with primer pairs JVO9585/JVO9548.
To generate the pBJ1 plasmid used for creating the Δrnc mutation in WUE2594, ˜600 bp upstream and downstream of the rnc gene were amplified with the primer pairs rnc1/rnc2 and rnc3/rnc4, respectively, using WUE2594 genomic DNA as template. The oligonucleotides were modified so as to introduce BamHI/EcoRI site at the 5′ and 3′ ends (respectively) of the upstream fragment, and EcoRIIHindIII sites at the 5′ and 3′ ends (respectively) of the downstream fragment. These fragments were cloned into the pBluescript II SK(+) vector (Invitrogen) along with an EcoRI-digested fragment of pUC4K (GE Healthcare) containing the kanamycin cassette, yielding the knock-out plasmid (pBJ1) that contains the kanamycin cassette flanked on either side by the upstream and downstream regions of rnc.
Short putative targets for strain 8013 CRISPR spacers 1 (30 nts), 16 (50 nts), 23 (50 nts), and 25 (50 nts) were created by annealing synthetic oligonucleotide pairs OYZ001/OYZ002, OYZ007/OYZ008, OYZ011/OYZ012, and OYZ015/OYZ016, respectively. Longer (208, 350, 305, and 203 nt) putative targets for spacers 8, 9, 17, 18 of 8013 were PCR-amplified from the chromosomal DNAs of N. meningitidis strain MC58, N. gonorrhoea strain FA1090, and N. meningitidis strains MC58 and Z2491 respectively, and digested with AatII and PacI. Primer pairs for these PCRs were OYZ003/OYZ004, OYZ005/OYZ006, OYZ009/OYZ010, and OYZ013/OYZ014, respectively. All eight of these putative targets were ligated into pGCC2 via AatII and PacI sites, to create pGCC2 derivatives for interference tests.
pYZEJS040 (pSTblue-1/siaA+CAT+ctrA) was constructed by PCR-amplifying three individual fragments: a 562 nt siaA fragment from 8013 chromosomal DNA using primers OYZ036/OYZ037; a 561 nt ctrA fragment from 8013 chromosomal DNA using primers OYZ040/OYZ041; and a 1239 nt CAT cassette from the pGCCS vector using primers OYZ038/OYZ039. 100 ng of each of the three fragments were added to a 50 PCR reaction without any primers. After 15 cycles of PCR, outside primers OYZ036/OYZ041 were added and 20 more cycles were performed. The ends of the 2.3 kb fusion product siaA-CAT-ctrA were blunted, and the fragment was ligated into the EcoRV site of pSTblue-1 to yield pYZEJS040. The pYZEJS040 derivatives used in interference tests were generated by ligating potential targets for 8013 CRISPR spacers 9 and 25 into pYZEJS040 via the AatII and PacI sites.
To construct plasmid pCR2.1/cas1-Kan, a 2.4 kb insert was PCR-amplified from the chromosomal DNA of NeMeSys strain 10/4 (Rusniok et al., 2009) using primers OYZ060/OYZ061. This insert, which contains a 1.6 kb KanR transposon inserted into the cas1 gene, was cloned using Original TA Cloning Kit pCR2.1 (Invitrogen) according to the manufacturer's instructions. Similarly, plasmid pCR2.1/cas2-Kan was created by amplifying a 2.45 kb insert from the chromosomal DNA of NeMeSys strain 71/27 using primers OYZ052/OYZ055, and cloning that fragment into pCR2.1.
To create plasmids to be used in generating the unmarked Δcas9 mutant, genomic sequences upstream and downstream of cas9 gene were PCR amplified, fused together via overlapping PCR and cloned into pSTblue-1. A 662 nt region containing the first 15 nt of the cas9 ORF and 632 nt upstream of cas9 was PCR-amplified from 8013 genomic DNA using primers OYZ066/OYZ068. Similarly, a 517 nt region containing the last 15 nt of the cas9 ORF and 487 nt downstream of cas9 was amplified using primers OYZ069/OYZ071. 100 ng of both PCR fragments were added to a 50 μl PCR reaction without any primers. After 15 cycles of PCR, outside primers OYZ066/OYZ071 were added and 20 more PCR cycles were performed. The resulting 1.2 kb fusion product included internal Sall and Spel sites (originally incorporated in the primers). The ends of the fragment were blunted, and the product was ligated into the EcoRV site of pSTblue-1 to create plasmid pSTblue-1/Δcas9+SalI-SpeI. The SalI and SpeI sites of this plasmid were used to introduce a 1.6 kb CAT-rpsL dual marker cassette, and resulted in pSTblue-1/Δcas9/CAT-rpsL. The plasmid pSTblue-1/Δcas9 was generated similarly: 647 nt and 502 nt genomic fragments upstream and downstream of the cas9 gene, including the 15 nts at each terminus of the ORF, were amplified using primers OYZ066/OYZ067 and OYZ070/OYZ071, respectively, and then fused together by overlapping PCR. The 1.2 kb fusion product was blunted and ligated into the EcoRV site of pSTblue-1.
To create pSMARTHCAmp/Δtracr+PmeI, genomic sequences upstream and downstream of the tracrRNA region were PCR amplified and fused together via overlapping PCR. The 638 nt upstream region and the 598 nt downstream region were amplified from 8013 chromosomal DNA using primer pairs OYZ081/OYZ082 and OYZ083/OYZ084, respectively. 100 ng of both fragments were added to a 50 μl PCR reaction without any primers, and after 15 cycles, outside primers OYZ081/OYZ084 were added and 20 more cycles were performed. The 1.2 kb fusion product included an internal PmeI site (designed in the primers). The fragment was blunted and ligated into vector pSMARTHCAMP according to the instructions for the CloneSmart Cloning Kit (Lucigen). The PmeI site was used to insert a 1.2 kb KanR cassette that had been amplified from NeMeSys mutant 23/6 chromosomal DNA using primer pair OYZ085/OYZ086. This yielded plasmid pSMARTHCAmp/Δtracr+Kan.
Complementation plasmid pGGC2/promoter+cas9wt was created by amplifying the cas9 ORF and its native promoter from 8013 genomic DNA using primer pair OYZ072/OYZ073, digesting the PCR product with AatII and PacI, and then ligating it into pGCC2 via the AatII/PacI sites. pGGC2/promoter+tracr was created by amplifying the tracrRNA locus with its native promoter from 8013 genomic DNA using primer pair OYZ091/OYZ092, digesting the PCR product with AatII and PacI, then ligating it into pGCC2 via the AatII/PacI sites.
Neisseria: CRISPR-repeat
Neisseria: mutant CRISPR-repeat
Neisseria: 3x CRISPR-repeat-spacer
Campylobacter jejuni: CRISPR-repeat
RNA Extraction, Depletion of Processed RNAs, and Northern Blots. For 020-06, WUE2594 and its mutant derivatives, frozen cell pellets from liquid cultures were resuspended in lysis solution containing 800 μl of 0.5 mg/ml lysozyme in TE buffer (pH 8.0) and 80 μl 10% SDS. Bacterial cells were lysed by placing the samples for 1-2 minutes at 65° C. in a water bath. Afterwards, total RNA was extracted from the lysates using the hot-phenol method described previously (Blomberg et al., 1990). For depletion of processed transcripts, total RNA was freed of residual genomic DNA by DNase I treatment, and equal amounts of Neisseria RNA were incubated with Terminator 5′-phosphate-dependent exonuclease (TEX) (Epicentre) or in buffer alone as previously described (Sharma et al., 2010). For northern blot analysis, 5 μg total RNA freed of residual genomic DNA or 3 μg of TEX treated RNA was loaded per sample. After separation by electrophoresis in 8% polyacrylamide/8.3 M urea/1x TBE gels, RNA was transferred onto Hybond-XL membranes, and membranes were hybridized with γ-32P-ATP end-labeled oligodeoxyribonucleotide probes.
For 8013 and its mutant derivatives, cells grown overnight on GCB plates were collected, immediately treated with RNAprotect Bacteria Reagent (Qiagen), and frozen at −80° C. for storage. Total RNAs were extracted using miRNeasy Mini Kit (Qiagen) with two additional steps: a 10 min initial cell lysis in 30 mM Tris-HCl (pH 8.0)/1 mM EDTA containing 1.5 mg/ml lysozyme (Invitrogen) and 2 mg/ml Proteinase K (Fermentas), and a later on-column DNase digestion step (The RNase-Free DNase Set, Qiagen). For northern analysis, 8-10 μg of total RNA for each sample was separated by electrophoresis in a 10% polyacrylamide/8 M urea/1×TBE gel. RNAs were electroblotted overnight at 14V to a Genescreen Plus membrane (PerkinElmer) in 1×TBE, cross-linked to the membrane by UV irradiation and then soaking in 0.16M N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride/0.13 M 1-methylimidazole (both from Sigma) (pH 8.0) at 60° C. for 2 h. Blots were prehybridized with 8 ml ULTRAhyb buffer (Ambion) at 60° C. for 30 min, then probed at 37° C. overnight with 5×106 cpm/ml of the appropriate DNA oligonucleotide probe. Northern probes were 5′ end-labeled with γ-32P-ATP (PerkinElmer) and T4 polynucleotide kinase (NEB). The membranes were washed at room temperature twice with 2×SSC/0.1% SDS for 5 min and then twice with 1×SSC/0.1% SDS for 15 min. RNAs were then visualized by PhosphorImager detection. Similarly end-labeled MspI-digested pBR322 DNAs (NEB) were used as size markers.
Construction of cDNA Libraries for dRNA-seq. Total RNA was freed of residual genomic DNA by DNase I treatment. For depletion of processed transcripts, equal amounts of Neisseria RNA were incubated with Terminator™ 5′-phosphate dependent exonuclease (TEX) (Epicentre) as previously described (Sharma et al., 2010). Libraries for Solexa sequencing (HiSeq) of cDNA were constructed by vertis Biotechnology AG, Germany (http://www.vertis-biotech.com/), as described previously for eukaryotic microRNA (Berezikov et al., 2006) but omitting the RNA size-fractionation step prior to cDNA synthesis. In brief, equal amounts of RNA samples were poly(A)-tailed using poly(A) polymerase. Then, the 5′-triphosphate structures were removed using tobacco acid pyrophosphatase (TAP). Afterwards, an RNA adapter was ligated to the 5′-phosphate of the RNA. First-strand cDNA was synthesized by an oligo(dT)-adapter primer and MMLV reverse transcriptase. A PCR-based amplification step with a high-fidelity DNA polymerase was then used to increase the cDNA concentration to 20-30 ng/μl. A library-specific barcode for sequence multiplexing was included in the 3′-sequencing adapter. cDNA libraries were sequenced using a HiSeq 2000 machine (Illumina) in single read mode at the Max Planck Genome Centre Cologne (Cologne, Germany).
Read Mapping and Coverage Plot Construction. Sample preparation, sequencing (Illumina GAIIx) and data analysis was done as described (Chao et al., 2012), with the only exception being that the minimal read length after trimming and clipping was 12 nt instead of 20 nt.
Transcriptional gfp Fusions. E. coli cells were transformed with transcriptional gfp fusion plasmids and grown on agar plates for fluorescence imaging. To measure GFP fluorescence, single colonies were inoculated in LB broth and grown for 12 h. Cells were then fixed in 4% paraformaldehyde/1x PBS and analysed by flow cytometry.
In vitro Transcription. Templates for in vitro transcription assays were PCR-generated, gel-purified 210 bp DNA fragments amplified from pNH13, pNH14, or pNH15. Primer pairs were the forward primers used for construction of each DNA duplex insert (see above), together with reverse primer JVO155. Templates (100 ng) were incubated at 37° C. in transcription buffer (40 mM Tris—HCl (pH 7.5)/100 mM KCl/10 mM MgCl2/0.01% Triton/1 mM DTT) together with 1.5 Units sigma-saturated E. coli RNA Polymerase Holoenzyme (Epicentre), α-[32P]-ATP (30 μCi; Hartmann-Analytic Braunschweig), and NTP mix (10 μM ATP and 200 μM each CTP, GTP, UTP). A negative control reaction used water in place of DNA template. 25 μl reactions were incubated for 1, 5, 10 and 30 min. Aliquots were phenol-extracted, precipitated, denatured by heating in formamide loading dye, separated by electrophoresis in 12% sequencing gels, and analyzed with a PhosphorImager.
CRISPR prediction and in silico Analysis of Natural Targets. CRISPRs in sequenced Neisseria genomes were predicted using CRISPRfinder (http://crispr.u-psud.fr/Server/) (Grissa et al., 2007) and CRISPRI (http://crispi.genouest.org/) (Rousseau et al., 2009). Our initial predictions of Neisseria CRISPRs were consistent with those of CRISPRdb (http://crispr.u-psud.fr/crispr/). Spacers were subjected to blastn (Basic Local Alignment Search Tool) search against the nr/nt database (http://www.ncbi.nlm.nih.gov/). Multiple Sequence Alignments were performed using WebLogo (http://weblogo.berkeley.edu/logo.cgi).
Natural Transformation. Natural transformation assays were performed in N. meningitidis 8013 and its mutant derivatives as described for N. gonorrhoeae (Duffin and Seifert, 2012). 150 ng plasmids or 100 ng chromosomal DNA was used per transformation reaction. 10 μl of serial 10-fold dilutions were spotted on GCB plate in triplicates in the presence and absence of appropriate antibiotics. 200 μl from the undiluted final transformation mixture were also plated on GCB plates with appropriate antibiotics to enhance detection. Eight representative transformants per reaction were verified by re-streaking on selective plates twice and then by PCR from CLS extract (i.e., from cells lysed in 1% Triton/20 mM Tris-HCl (pH 8.3)/2 mM EDTA at 94° C. for 15 min and then 20° C. for 5 min). Transformation frequencies were reported as antibiotic-resistant cfu/ml divided by total cfu/ml from at least three independent experiments (mean±s.e.m.).
References for Example 1
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., and Horvath, P. (2007). CRISPR provides acquired resistance against viruses in prokaryotes. Science 315, 1709-1712.
Bart, A., Barnabé, C., Achtman, M., Dankert, J., van der Ende, A., and Tibayrenc, M. (2001). The population structure of Neisseria meningitidis serogroup A fits the predictions for clonality. Infect. Genet. Evol. 1, 117-122.
Bennett, J. S., Bentley, S. D., Vernikos, G. S., Quail, M. A., Cherevach, I., White, B., Parkhill, J., and Maiden, M. C. J. (2010). Independent evolution of the core and accessory gene sets in the genus Neisseria: insights gained from the genome of Neisseria lactamica isolate 020-06. BMC Genomics 11, 652.
Bhaya, D., Davison, M., and Barrangou, R. (2011). CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. Annu. Rev. Genet. 45, 273-297.
Bikard, D., Hatoum-Aslan, A., Mucida, D., and Marraffini, L. A. (2012). CRISPR interference can prevent natural transformation and virulence acquisition during in vivo bacterial infection. Cell Host & Microbe 12, 177-186.
Bille, E., Ure, R., Gray, S. J., Kaczmarski, E. B., McCarthy, N. D., Nassif, X., Maiden, M. C. J., and Tinsley, C. R. (2008). Association of a bacteriophage with meningococcal disease in young adults. PloS One 3, e3885.
Bille, E., Zahar, J.-R., Perrin, A., Morelle, S., Kriz, P., Jolley, K. A., Maiden, M. C. J., Dervin, C., Nassif, X., and Tinsley, C. R. (2005). A chromosomally integrated bacteriophage in invasive meningococci. J. Exp. Med. 201, 1905-1913.
Bolotin, A., Quinquis, B., Sorokin, A., and Ehrlich, S. D. (2005). Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology 151, 2551-2561.
Braid, M. D., Silha , J. L., Kitts, C. L., Cano, R. J., and Howe, M. M. (2004). Complete genomic sequence of bacteriophage B3, a Mu-like phage of Pseudomonas aeruginosa. J. Bact. 186, 6560-6574.
Bratcher, H. B., Bennett, J. S., and Maiden, M. C. J. (2012). Evolutionary and genomic insights into meningococcal biology. Future Microbiol. 7, 873-885.
Brouns, S. J. J., Jore, M. M., Lundgren, M., Westra, E. R., Slijkhuis, R. J. H., Snijders, A. P. L., Dickman, M. J., Makarova, K. S., Koonin, E. V., and Van der Oost, J. (2008). Small CRISPR RNAs guide antiviral defense in prokaryotes. Science 321, 960-964.
Buckee, C. O., Jolley, K. A., Recker, M., Penman, B., Kriz, P., Gupta, S., and Maiden, M. C. J. (2008). Role of selection in the emergence of lineages and the evolution of virulence in Neisseria meningitidis. Proc. Natl. Acad. Sci. USA 105, 15082-15087.
Budroni, S., Siena, E., Dunning Hotopp, J. C., Seib, K. L., Serruto, D., Nofroni, C., Comanducci, M., Riley, D. R., Daugherty, S. C., Angiuoli, S. V., et al. (2011). Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination. Proc. Natl. Acad. Sci. USA 108, 4494-4499.
Carte, J., Wang, R., Li, H., Terns, R. M., and Terns, M. P. (2008). Cas6 is an endoribonuclease that generates guide RNAs for invader defense in prokaryotes. Genes Dev. 22, 3489-3496.
Cehovin, A., Simpson, P. J., McDowell, M. A., Brown, D. R., Noschese, R., Pallett, M., Brady, J., Baldwin, G. S., Lea, S. M., Matthews, S. J., and Pelicic, V. (2013). Specific DNA recognition mediated by a type IV pilin. Proc. Natl. Acad. Sci. USA 110, 3065-3070.
Chao, Y., Papenfort, K., Reinhardt, R., Sharma, C. M., and Vogel, J. (2012). An atlas of Hfq-bound transcripts reveals 3′ UTRs as a genomic reservoir of regulatory small RNAs. EMBO J. 31, 4005-4019.
Chen, I., Christie, P. J., and Dubnau, D. (2005). The ins and outs of DNA transfer in bacteria. Science 310, 1456-1460.
Cho, S. W., Kim, S., Kim, J. M., and Kim, J.-S. (2013). Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nature Biotech. 31, 230-232.
Chylinski, K., Le Rhun, A., and Charpentier, E. (2013). The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems. RNA Biol., in press [ePub ahead of print (doi:10.4161/rna24321)].
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823.
Corander, J., Connor, T. R., O'Dwyer, C. A., Kroll, J. S., and Hanage, W. P. (2012). Population structure in the Neisseria, and the biological significance of fuzzy species. J. Royal Soc. Interface 9, 1208-1215.
Deltcheva, E., Chylinski, K., Sharma, C. M., Gonzales, K., Chao, Y., Pirzada, Z. A., Eckert, M. R., Vogel, J., and Charpentier, E. (2011). CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471, 602-607.
Deng, L., Kenchappa, C. S., Peng, X., She, Q., and Garrett, R. A. (2012). Modulation of CRISPR locus transcription by the repeat-binding protein Cbp1 in Sulfolobus. Nucleic Acids Res. 40,2470-2480.
Deveau, H., Barrangou, R., Garneau, J. E., Labonte, J., Fremaux, C., Boyaval, P., Romero, D. A., Horvath, P., and Moineau, S. (2008). Phage response to CRISPR-encoded resistance in Streptococcus thermophilus. J. Bact. 190, 1390-1400.
DiCarlo, J. E., Norville, J. E., Mali, P., Rios, X., Aach, J., and Church, G. M. (2013). Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems. Nucleic Acids Res. 41,4336-4343.
Duffin, P. M., and Seifert, H. S. (2012). Genetic transformation of Neisseria gonorrhoeae shows a strand preference. FEMS Microbiol. Letters 334, 44-48.
Edgar, R., and Qimron, U. (2010). The Escherichia coli CRISPR system protects from 1 lysogenization, lysogens, and prophage induction. J. Bact. 192, 6291-6294.
Feil, E. J., and Sprat, B. G. (2001). Recombination and the population structures of bacterial pathogens. Annu. Rev. Microbiol. 55, 561-590.
Garneau, J. E., Dupuis, M.-È., Villion, M., Romero, D. A., Barrangou, R., Boyaval, P., Fremaux, C., Horvath, P., Magadán, A. H., and Moineau, S. (2010). The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 468, 67-71.
Gasiunas, G., Barrangou, R., Horvath, P., and Siksnys, V. (2012). Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc. Natl. Acad. Sci. USA 109, 2579-2586.
Gesner, E. M., Schellenberg, M. J., Garside, E. L., George, M. M., and Macmillan, A. M. (2011). Recognition and maturation of effector RNAs in a CRISPR interference pathway. Nature Struct. Mol. Biol. 18, 688-692.
Grissa, I., Vergnaud, G., and Pourcel, C. (2007). The CRISPRdb database and tools to display CRISPRs and to generate dictionaries of spacers and repeats. BMC Bioinformatics 8, 172.
Gudbergsdottir, S., Deng, L., Chen, Z., Jensen, J. V. K., Jensen, L. R., She, Q., and Garrett, R. A. (2011). Dynamic properties of the Sulfolobus CRISPR/Cas and CRISPR/Cmr systems when challenged with vector-borne viral and plasmid genes and protospacers. Mol. Microbiol. 79, 35-49.
Haft, D. H., Selengut, J., Mongodin, E. F., and Nelson, K. E. (2005). A guild of 45 CRISPR-associated (Cas) protein families and multiple CRISPR/Cas subtypes exist in prokaryotic genomes. PLoS Comp. Biol. 1, e60.
Hale, C., Kleppe, K., Terns, R. M., and Terns, M. P. (2008). Prokaryotic silencing (psi)RNAs in Pyrococcus furiosus. RNA 14, 2572-2579.
Hale, C. R., Majumdar, S., Elmore, J., Pfister, N., Compton, M., Olson, S., Resch, A. M., Glover, C. V. C., Graveley, B. R., Terns, R. M., et al. (2012). Essential features and rational design of CRISPR RNAs that function with the Cas RAMP module complex to cleave RNAs. Mol. Cell 45, 292-302.
Hale, C. R., Zhao, P., Olson, S., Duff, M. O., Graveley, B. R., Wells, L., Terns, R. M., and Terns, M. P. (2009). RNA-guided RNA cleavage by a CRISPR RNA-Cas protein complex. Cell 139, 945-956.
Hamilton, H. L., and Dillard, J. P. (2006). Natural transformation of Neisseria gonorrhoeae: from DNA donation to homologous recombination. Mol. Microbiol. 59, 376-385.
Hanage, W. P., Fraser, C., and Sprat, B. G. (2005). Fuzzy species among recombinogenic bacteria. BMC Biol. 3,6.
Haurwitz, R. E., Jinek, M., Wiedenheft, B., Zhou, K., and Doudna, J. A. (2010). Sequence- and structure-specific RNA processing by a CRISPR endonuclease. Science 329, 1355-1358.
Hook-Barnard, LG., and Hinton, D. M. (2007). Transcription initiation by mix and match elements: flexibility for polymerase binding to bacterial promoters. Gene Reg. Systems Biol. 1, 275-293.
Horvath, P., Romero, D. A., Coûté-Monvoisin, A.-C., Richards, M., Deveau, H., Moineau, S., Boyaval, P., Fremaux, C., and Barrangou, R. (2008). Diversity, activity, and evolution of CRISPR loci in Streptococcus thermophilus. J. Bact. 190, 1401-1412.
Hwang, W. Y., Fu, Y., Reyon, D., Maeder, M. L., Tsai, S. Q., Sander, J. D., Peterson, R. T., Yeh, J.-R. J., and Joung, J. K. (2013). Efficient genome editing in zebrafish using a CRISPR-Cas system. Nature Biotech. 31, 227-229.
Jiang, W., Bikard, D., Cox, D., Zhang, F., and Marraffini, L. A. (2013). RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nature Biotech. 31, 233-239.
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., and Charpentier, E. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821.
Jinek, M., East, A., Cheng, A., Lin, S., Ma, E., and Doudna, J. (2013). RNA-programmed genome editing in human cells. eLife 2, e00471.
Jolley, K. A., and Maiden, M. C. J. (2010). BIGSdb: Scalable analysis of bacterial genome variation at the population level. BMC Bioinformatics 11, 595.
Joseph, B., Schwarz, R. F., Linke, B., Blom, J., Becker, A., Claus, H., Goesmann, A., Frosch, M., Müller, T., Vogel, U., et al. (2011). Virulence evolution of the human pathogen Neisseria meningitidis by recombination in the core and accessory genome. PloS One 6, e18441.
Karginov, F. V, and Hannon, G. J. (2010). The CRISPR system: small RNA-guided defense in bacteria and archaea. Mol. Cell 37, 7-19.
Kawai, M., Nakao, K., Uchiyama, I., and Kobayashi, I. (2006). How genomes rearrange: genome comparison within bacteria Neisseria suggests roles for mobile elements in formation of complex genome polymorphisms. Gene 383, 52-63.
Kawai, M., Uchiyama, I., and Kobayashi, I. (2005). Genome comparison in silico in Neisseria suggests integration of filamentous bacteriophages by their own transposase. DNA Research 12, 389-401.
Koonin, E. V., and Makarova, K. S. (2013). CRISPR-Cas: evolution of an RNA-based adaptive immunity system in prokaryotes. RNA Biol., in press [ePub ahead of print (doi:10.4161/rna24022)].
Magadan, A. H., Dupuis, M.-È., Villion, M., and Moineau, S. (2012). Cleavage of phage DNA by the Streptococcus thermophilus CRISPR3-Cas system. PLoS ONE 7, e40913.
Makarova, K.S., Aravind, L., Wolf, Y. I., and Koonin, E. V (2011a). Unification of Cas protein families and a simple scenario for the origin and evolution of CRISPR-Cas systems. Biol. Direct 6, 38.
Makarova, K. S., Grishin, N. V, Shabalina, S. A., Wolf, Y. I., and Koonin, E. V (2006). A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action. Biol. Direct 1, 7.
Makarova, K. S., Haft, D. H., Barrangou, R., Brouns, S. J. J., Charpentier, E., Horvath, P., Moineau, S., Mojica, F. J. M., Wolf, Y. I., Yakunin, A. F., et al. (2011b). Evolution and classification of the CRISPR-Cas systems. Nature Rev. Microbiol. 9, 467-477.
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., and Church, G. M. (2013). RNA-guided human genome engineering via Cas9. Science 339, 823-826.
Marraffini, L. A. and Sontheimer, E. J. (2008). CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. Science 322, 1843-1845.
Marraffini, L. A. and Sontheimer, E. J. (2010). CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea. Nature Rev. Genet. 11, 181-190.
Masignani, V., Giuliani, M. M., Tettelin, H., Comanducci, M., Rappuoli, R., and Scarlato, V. (2001). Mu-like Prophage in serogroup B Neisseria meningitidis coding for surface-exposed antigens. Infect. Immun. 69, 2580-2588.
Mojica, F. J. M., Díez-Villaseñor, C., García-Martínez, J., and Almendros, C. (2009). Short motif sequences determine the targets of the prokaryotic CRISPR defence system. Microbiology 155, 733-740.
Mojica, F. J. M., Díez-Villaseñor, C., Garcia-Martínez, J., and Soria, E. (2005). Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J. Mol. Evol. 60, 174-182.
Moxon, E. R., and Jansen, V. A. A. (2005). Phage variation: understanding the behaviour of an accidental pathogen. Trends Microbiol. 13, 563-565.
Palmer, K., and Gilmore, M. (2010). Multidrug-resistant enterococci lack CRISPR-cas. mBio 1, e00227-10.
Peng, J., Yang, L., Yang, F., Yang, J., Yan, Y., Nie, H., Zhang, X., Xiong, Z., Jiang, Y., Cheng, F., et al. (2008). Characterization of ST-4821 complex, a unique Neisseria meningitidis clone. Genomics 91, 78-87.
Pines, O., Yoon, H., and Inouye, M. (1988). Expression of double-stranded-RNA-specific RNase III of Escherichia coli is lethal to Saccharomyces cerevisiae. J. Bact. 170, 2989-2993.
Pourcel, C., Salvignol, G., and Vergnaud, G. (2005). CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. Microbiology 151, 653-663.
Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., and Lim, W. A. (2013). Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152, 1173-1183.
Rousseau, C., Gonnet, M., Le Romancer, M., and Nicolas, J. (2009). CRISPRi: a CRISPR interactive database. Bioinformatics 25, 3317-3318.
Rusniok, C., Vallenet, D., Floquet, S., Ewles, H., Mouzé-Soulama, C., Brown, D., Lajus, A., Buchrieser, C., Médigue, C., Glaser, P., et al. (2009). NeMeSys: a biological resource for narrowing the gap between sequence and function in the human pathogen Neisseria meningitidis. Genome Biol. 10, R110.
Sampson, T. R., Saroj, S. D., Llewellyn, A. C., Tzeng, Y.-L., and Weiss, D. S. (2013). A CRISPR/Cas system mediates bacterial innate immune evasion and virulence. Nature, in press [ePub ahead of print (doi:10.1038/nature12048)].
Sapranauskas, R., Gasiunas, G., Fremaux, C., Barrangou, R., Horvath, P., and Siksnys, V. (2011). The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli. Nucleic Acids Res. 39, 9275-9282.
Sashital, D. G., Wiedenheft, B., and Doudna, J. A. (2012). Mechanism of foreign DNA selection in a bacterial adaptive immune system. Mol. Cell 46, 606-615.
Semenova, E., Jore, M. M., Datsenko, K. A., Semenova, A., Westra, E. R., Wanner, B., van der Oost, J., Brouns, S. J. J., and Severinov, K. (2011). Interference by clustered regularly interspaced short palindromic repeat (CRISPR) RNA is governed by a seed sequence. Proc. Natl. Acad. Sci. U.S.A. 108, 10098-10103.
Sharma, C. M., Hoffmann, S., Darfeuille, F., Reignier, J., Findeiss, S., Sittka, A., Chabas, S., Reiche, K., Hackermũller, J., Reinhardt, R., et al. (2010). The primary transcriptome of the major human pathogen Helicobacter pylori. Nature 464, 250-255.
Sittka, A., Lucchini, S., Papenfort, K., Sharma, C. M., Rolle, K., Binnewies, T. T., Hinton, J. C. D., and Vogel, J. (2008). Deep sequencing analysis of small noncoding RNA and mRNA targets of the global post-transcriptional regulator, Hfq. PLoS Genet. 4, e1000163.
Sittka, A., Pfeiffer, V., Tedin, K., and Vogel, J. (2007). The RNA chaperone Hfq is essential for the virulence of Salmonella typhimurium. Molec. Microbiol. 63, 193-217.
Skaar, E. P., Lecuyer, B., Lenich, A. G., Lazio, M. P., Perkins-Balding, D., Seifert, H. S., and Karls, A. C. (2005). Analysis of the Piv recombinase-related gene family of Neisseria gonorrhoeae. J. Bact. 187, 1276-1286
Smith, J. M., Smith, N. H., O'Rourke, M., and Spratt, B. G. (1993). How clonal are bacteria? Proc. Natl. Acad. Sci. USA 90, 4384-4388.
Stephens, D. S., Greenwood, B., and Brandtzaeg, P. (2007). Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 369, 2196-2210.
Stern, A., Keren, L., Wurtzel, O., Amitai, G., and Sorek, R. (2010). Self-targeting by CRISPR: gene regulation or autoimmunity? Trends Genet. 26, 335-340.
Terns, M. P., and Terns, R. M. (2011). CRISPR-based adaptive immune systems. Curr. Opin. Microbiol. 14, 321-327.
Tobiason, D. M., and Seifert, H. S. (2010). Genomic content of Neisseria species. J. Bact. 192, 2160-2168.
van Passel, M. W. J., Van der Ende, A., and Bart, A. (2006). Plasmid diversity in neisseriae. Infect. Immun. 74, 4892-4899.
Vázquez, J. A., de la Fuente, L., Berron, S., O'Rourke, M., Smith, N. H., Zhou, J., and Spratt, B. G. (1993). Ecological separation and genetic isolation of Neisseria gonorrhoeae and Neisseria meningitidis. Curr. Biol. 3,567-572.
Westra, E. R., Van Erp, P. B. G., Ktinne, T., Wong, S. P., Staals, R. H. J., Seegers, C. L. C., Bollen, S., Jore, M. M., Semenova, E., Severinov, K., et al. (2012). CRISPR immunity relies on the consecutive binding and degradation of negatively supercoiled invader DNA by Cascade and Cas3. Mol. Cell 46, 595-605.
Wiedenheft, B., Van Duijn, E., Bultema, J.B., Bultema, J., Waghmare, S. P., Waghmare, S., Zhou, K., Barendregt, A., Westphal, W., Heck, A. J. R., et al. (2011). RNA-guided complex from a bacterial immune system enhances target recognition through seed sequence interactions. Proc. Natl. Acad. Sci. USA 108, 10092-10097.
Wiedenheft, B., Sternberg, S. H., and Doudna, J. A. (2012). RNA-guided genetic silencing systems in bacteria and archaea. Nature 482, 331-338.
Yosef, I., Goren, M. G., and Qimron, U. (2012). Proteins and DANN elements essential for the CRISPR adaptation process in Escherichia coli. Nucleic Acids Res. 40, 5569-5576.
Zhang, J., Rouillon, C., Kerou, M., Reeks, J., Brugger, K., Graham, S., Reimann, J., Cannone, G., Liu, H., Albers, S.-V., et al. (2012). Structure and mechanism of the CMR complex for CRISPR-mediated antiviral immunity. Mol. Cell 45, 303-313.
Reference is made to Hou et al., “Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis, PNAS, vol. 110, no. 39, pp 15644-15649, Sep. 24, 2013, the contents of which are incorporated herein by reference in its entirety.
Abstract
Genome engineering in human pluripotent stem cells holds great promise for biomedical research and regenerative medicine. Recently, an RNA-guided, DNA-cleaving interference pathway from bacteria [the Type II clustered, regularly interspaced, short palindromic repeats (CRISPR)-CRISPR-associated (Cas) pathway] has been adapted for use in eukaryotic cells, greatly facilitating genome editing. Only two CRISPR-Cas systems (from Streptococcus pyogenes and Streptococcus thermophilus), each with their own distinct targeting requirements and limitations, have been developed for genome editing thus far. Furthermore, limited information exists about homology-directed repair (HDR)-mediated gene targeting using long donor DNA templates in human pluripotent stem cells (hPSCs) with these systems. Here, using a distinct CRISPR-Cas system from Neisseria meningitidis, we demonstrate efficient targeting of an endogenous gene in three hPSC lines using HDR. The Cas9 RNA-guided endonuclease from N. meningitidis (NmCas9) recognizes a 5′-NNNNGATT-3′ protospacer adjacent motif (PAM) different from those recognized by Cas9 proteins from S. pyogenes and S. thermophilus (SpCas9 and StCas9, respectively). Similar to SpCas9, NmCas9 is able to use a single-guide RNA (sgRNA) to direct its activity. Due to its distinct PAM, the N. meningitidis CRISPR-Cas machinery increases the sequence contexts amenable to RNA-directed genome editing.
Introduction
Human pluripotent stem cells (hPSCs) can proliferate indefinitely while maintaining the potential to give rise to virtually all human cell types (1). They are therefore invaluable for regenerative medicine, drug screening, and biomedical research. However, to realize the full potential of hPSCs, it will be necessary to manipulate their genomes in a precise, efficient manner. Historically, gene targeting in hPSCs has been extremely difficult (2). The development of zinc-finger nucleases (ZFNs) and transcription activator-like endonucleases (TALENs) (reviewed in refs. (3) and (4)) has facilitated gene targeting in hPSCs (5-7). Nonetheless, they require the design, expression, and validation of a new pair of proteins for every targeted locus, rendering both of these platforms time-consuming and labor-intensive (8-10).
Clustered, regularly interspaced, short palindromic repeat (CRISPR) loci, along with CRISPR-associated (cas) genes, underlie an adaptive immune system of bacteria and archaea that defends against bacteriophages (11) and limits horizontal gene transfer (12-14). “Protospacer” sequences from invading nucleic acids are incorporated as “spacers” within CRISPRs, conferring immunity and providing a genomic memory of past invasions. CRISPR-Cas systems have been classified into three types (Types I, II and III) and numerous subtypes (15). All use short CRISPR RNAs (crRNAs) (16, 17) to specify genetic interference via the destruction of invading nucleic acids (18). The target nucleic acids are recognized by crRNA Watson-Crick pairing. Importantly, most CRISPR-Cas subtypes target DNA directly (13, 19, 20), suggesting the possibility of engineered, RNA-directed gene targeting/editing systems. The use of RNA guides for gene targeting would confer many advantages over ZFNs and TALENs, especially by obviating the need for repeated protein design/optimization. Recently, this vision has become a reality (21-31).
Type II CRISPR-Cas systems are noteworthy in that the essential targeting activities—crRNA binding, target DNA binding, R-loop formation, and double-stranded DNA cleavage—are all executed by a single polypeptide, Cas9 (32-35). In addition to crRNA and Cas9, an additional RNA, trans-acting CRISPR RNA (tracrRNA), is essential for interference in bacteria (14, 32, 36) and in vitro (34, 36). The tracrRNA is partially complementary to pre-crRNA repeats, leading to the formation of duplexes that are cleaved by the host factor ribonuclease III (RNase III) (32). The Type II crRNA maturation pathway was originally characterized in strains of Streptococcus pyogenes (32) and Streptococcus thermophilus (35, 36), and RNase III-catalyzed pre-crRNA processing is essential for interference in both native systems. Recent studies of a Type II CRISPR-Cas locus from Neisseria meningitidis revealed an intrinsically RNase III- and processing-independent system, which nonetheless requires tracrRNA (14). Importantly, crRNA-directed DNA cleavage was reconstituted in vitro with recombinant S. pyogenes Cas9 (SpCas9) (34) or S. thermophilus Cas9 (StCas9) (33, 36). The SpCas9 in vitro system enabled the development of fused crRNA-tracrRNA chimeras called single-guide RNAs (sgRNAs) that bypass processing (34). Subsequent development of eukaryotic genome editing applications has focused on sgRNAs (21-30), though separately encoded pre-crRNAs and tracrRNAs are also effective (21).
Target cleavage by many CRISPR/Cas systems, including those from Type II, require proximity to a 2-5 nucleotide (nt) sequence called a protospacer adjacent motif (PAM) (37) (38-40). Genome editing applications reported thus far have focused almost exclusively on SpCas9, which has a 5′-NGG-3′ PAM. StCas9 (from the CRISPR1 locus of strain LMD-9) has also been used in eukaryotes (21), and that system has a 5′-NNAGAAW-3′ PAM (W=A or T). Eukaryotic editing capabilities will benefit from the increased frequency of target sites stemming from the development of additional Cas9s with distinct PAMs.
Targeting by sgRNAs usually relies on either of two approaches. First, double-strand break (DSB) repair by nonhomologous end joining (NHEJ) can be used to generate insertions or deletions (indels) that induce frame shifts. Second, the addition of a homologous repair template can allow Cas9-induced DSBs or nicks to be repaired by homology-directed repair (HDR). The latter strategy is useful for making precise changes such as repairing mutations or inserting transgenes. Most studies thus far have relied on either NHEJ, or on HDR using short DNA fragments or oligos (24-26, 29, 31). Currently there is very limited information available on gene targeting using long DNA donor templates in hPSCs (23).
Here, we report the development of N. meningitidis Cas9 (NmCas9) (14) as a genome editing platform, and its application to high-efficiency targeting of an endogenous gene in hPSCs. This system uses a 24 nt proto-spacer for targeting and requires a PAM that is different from those of SpCas9 or StCas9. We have achieved ˜60% targeting efficiency with two human embryonic stem cell (hESC) lines and one human induced pluripotent stem (iPS) cell line. Our work demonstrates the feasibility of using the N. meningitidis CRISPR/Cas system in genome editing in hPSCs using long DNA donor templates. This work also provides an alternative to the S. pyogenes and S. thermophilus CRISPR-Cas system and expands the genomic contexts that are amenable to RNA-directed genome editing in eukaryotes.
Results
Functional Expression of NmCas9 in Mammalian Cells. Our recent work has shown that N. meningitidis strain 8013 has a functional type II-C CRISPR/Cas system (14), and that Cas9 is the only Cas protein required for interference activity. We set out to test whether this system could be used for efficient gene targeting in hPSCs. We cloned the open reading frame (ORF) from the 3.25 kb cas9 gene, along with a C-terminal FLAG tag, into a mammalian expression plasmid under the control of an EF1α promoter (
Two Cas9 orthologs, SpoCas9 and StCas9, were previously demonstrated to induce blunt double-strand breaks (DSB) in their DNA targets, between the third and fourth nucleotide counting from the PAM-proximal end of protospacers (34) (19, 33). We hypothesized that NmCas9 cleaves the DNA target in a similar way, and we tested this by mapping the NmCas9 cleavage site on ptdTomato by Sanger sequencing. Two cleavage products in
NmCas9 Functions in RNA-Directed Gene Disruption in hPSCs. Knowing that NmCas9, without any codon optimization, can be efficiently expressed in mammalian cells and is functional in vitro, we next tested its utility in genome editing in hPSCs. We first monitored its localization. We transfected 293FT cells with several NmCas9 constructs with various nuclear localization signal (NLS) arrangements, and analyzed NmCas9 protein localization by either GFP fluorescence or anti-HA immunostaining. NmCas9 with NLSs on both N- and C-termini localized efficiently to the nucleus (
To test the genome editing activity of NmCas9, we used an hESC cell reporter line that has a single copy of the tdTomato fluorescent protein gene knocked into the highly expressed DNMT3b locus (H9 DNMT3b-tdTomato), leading to tdTomato fluorescence. If NmCas9 is able to introduce a DSB in the tdTomato sequence in the genome, repair by NHEJ would likely lead to indels that disrupt tdTomato expression. Accordingly, the appearance of tdTomato-negative cells would be predicted to reflect genome-editing activity.
Human ESCs are known to have low transfection efficiencies. To achieve maximum genome-editing efficiency in hPSCs, we assembled expression cassettes of all the necessary components (NmCas9, tracrRNA and crRNA) onto one single plasmid that contains an OriP sequence (
To confirm that NmCas9 introduced a DSB at the intended genomic site, we FACS-sorted the tdTomato negative population, PCR-amplified the genomic region flanking the predicted cutting site in the 5′ copy of dTomato, cloned the resulting PCR fragments and sequenced 22 of the resulting plasmids (selected at random). The sequencing results showed both insertions and deletions in the tdTomato sequence (
A Chimeric sgRNA is Effective for Gene Editing in hPSCs. To simplify the NmCas9 genome editing system, we explored the possibility of substituting both crRNA and tracrRNA with a chimeric sgRNA. We fused the 5′ end of the 91 nt processed tracrRNA sequence with the 3′ end of the 48 nt mature crRNA using a 6 nt linker (Supp.
Specificity of NmCas9 in hPSCs. We next tested the specificity of NmCas9 in mammalian cells by mutational analysis. We introduced single-nucleotide mutations at every odd-numbered position from the 1st to the 17th nt in the PAM-proximal end [spanning the cleavage site (see
We also investigated PAM sequence requirements for NmCas9 in human ES cells. We designed five crRNAs that use different sequences as the PAM in the tdTomato coding region (
NmCas9 Increases Gene Targeting Efficiency in hPSCs. We next explored whether NmCas9 can increase gene-targeting efficiency in hPSCs compared to the traditional method in which no DSB was intentionally introduced at the target site. We used a donor DNA template previously used to target the endogenous POU5F1 (OCT4) gene (6) (
Discussion
Genome Editing by N. meningitidis Cas9. In this report, we have successfully used the Type II-C CRISPR-Cas system from N. meningitidis to achieve both NHEJ-mediated gene editing and long DNA donor-directed gene targeting of an endogenous locus in hPSCs. The targeting efficiency we obtain with NmCas9 is comparable to that achieved with TALENs. Using the same donor construct, we were able to get ˜60% targeting efficiency in all three different hPSC lines tested (Table 7), whereas the targeting efficiency of a TALEN was 48% in the one hESC line tested (6). A previous report using SpCas9 in human iPSCs achieved a targeting efficiency of 43%, close to what we observed with NmCas9 (6). However, that report only identified seven clones and did not perform further analysis to confirm the correct integration of the donor DNA sequence only at the intended site. Therefore additional work will be needed to compare the efficiency of mammalian gene targeting using these two CRISPR-Cas systems.
CrRNA/Target Mismatch Tolerance by NmCas9 in Mammalian Cells. One potential advantage of NmCas9, relative to SpCas9, is that it might offer better targeting specificity by virtue of its longer crRNA spacer (24 vs. 20 nts) and its longer PAM (14). We chose 24 nt as the crRNA spacer length for NmCas9 because that is the length of the crRNA spacer in N. meningitidis. CrRNA-target mismatches distant from the PAM were tolerated to various extents for both NmCas9 (
PAM requirements in mammalian cells. One hallmark of Type II CRISPR-Cas systems is the requirement of a nearby PAM on the target sequence. This sequence varies between different Cas9 orthologs. Among Cas9 proteins validated for mammalian genome editing, PAM functional requirements have been defined for three: those from S. pyogenes SF370 (21-23, 32, 34), S. thermophilus LMD-9 (the CRISPR1 locus) (19, 21, 38), and N. meningitidis 8013 (FIG. 15B) (14). On one hand, the PAM requirement adds a second layer of specificity for gene targeting, beyond that afforded by spacer/protospacer complementarity. For longer PAMs (such as the NmCas9 PAM, 5′-NNNNGATT-3′), the frequency of off-target cutting events should potentially drop significantly compared to SpCas9, which requires a 5′-NGG-3′ PAM. On the other hand, longer PAM requirements also constrain the frequency of targetable sites. By developing genome-editing systems using a range of Cas9 proteins with distinct PAM requirements, the genomic regions that can be targeted by CRISPR-Cas editing would expand significantly.
The results in
Editing the Genomes of hPSCs. Compared to two other widely used systems for enhancing gene targeting efficiency (ZFNs and TALENs), the CRISPR-Cas system offers a much simpler and more user-friendly design. For each different genomic locus to be targeted, one only needs to design a small RNA by applying simple Watson-Crick base-pairing rules. This system's ease of use will make gene targeting in hPSCs, once considered a difficult project, a routine lab technique. This simple and high efficiency gene targeting system for hPSC will also have a tremendous impact on personalized regenerative medicine. One concern with using CRISPR/Cas in human genome editing is off-target cleavage. Our work (
Materials and Methods
Cell Culture. Human ESCs and iPS cells were cultured in E8™ medium (43) on Matrigel-coated tissue culture plates with daily media change at 37° C. with 5% CO2. Cells were split every 4-5 days with 0.5 mM EDTA in 1x PBS. 293FT cells were cultured similarly in DMEM/F12 media supplemented with 10% FBS.
NmCas9 DNA Transfection and In Vitro Plasmid Digestion. All transfections with 293FT cells were done using Fugene HD (Promega) following the manufacturer's instructions. Cell lysate was prepared two days after transfection. Plasmid digestion using cell lysate was carried out at 37° C. for 1-4 hours in digestion buffer (lx PBS with 10 mM MgCl2). See supplemental method for a detailed procedure. To map the cleavage site of NmCas9, the digested plasmid DNA was excised from the agarose gel and purified using Gel Extraction Kit (Qiagen). The purified fragments were then sequenced to map the cleavage site.
Gene Editing in hPSCs. All plasmids used in this experiment were purified using the MaxiPrep Kit from Qiagen. Human PSCs were passaged two or three days before the experiments. Immediately before the experiment, hPSCs were individualized by Accutase® treatment, washed once with E8™ medium, and resuspended at densities of 2.5-6.2×106 cells/ml in E8™ medium with 10 mM HEPES buffer (pH 7.2-7.5) (Life Technologies). For electroporation, 400 μl of cell suspension, 15 μg of pSimple-Cas9-Tracr-CrRNA plasmid, 5 μg of EBNA RNA, and (for those experiments involving gene targeting by HDR) 5 μg of linearized DNA template plasmid (Addgene 31939) were mixed in a 4 mm cuvette (BioRad) and immediately electroporated with a BioRad Gene Pulser. Electroporation parameters were 250V, 500 μF, and infinite resistance. Cells were then plated into appropriate Matrigel coated culture dishes in E8™ medium supplemented with 10 μM ROCK inhibitor Y-27632. Media was changed the next day to E8™ medium. For those experiments involving gene editing by HDR, puromycin selection was started 4 days after electroporation. Surviving colonies were picked 4 to 6 days after selection and expanded in E8™ medium.
Plasmid Construction. The cas9 gene from Neisseria meningitidis strain 8013 was PCR-amplified and cloned into the pSimpleII plasmid (an OriP containing plasmid) under the control of the EF1α promoter. Nuclear localization signals and HA tag sequences were incorporated via the PCR primers. An N. meningitidis BsmBI-crRNA cassette and the N. meningitidis tracrRNA, both under the control of U6 RNA polymerase III promoters, were synthesized as gene blocks (Integrated DNA Technologies) and cloned into pSimplell-Cas9 via blunt end cloning, generating the pSimple-Cas9-Tracr-BsmBI plasmid that includes all elements needed for targeting. To insert specific spacer sequences into the crRNA cassette, synthetic oligonucleotides containing the desired spacer sequences were annealed to generate a duplex with overhangs compatible with those generated by BsmBI digestion of the pSimple-Cas9-Tracr-BsmBI plasmid. The insert was then ligated into the BsmBI-digested plasmid.
NmCas9 DNA Transfection and In Vitro Plasmid Digestion. All transfections with 293FT cells were done using Fugene® HD (Promega) following the manufacture's instructions. Roughly 2 μg plasmids and 6 μl of Fugene HD were used for one well of a 6-well plate. Two days after transfection, 293FT cells expressing NmCas9 were harvested by TrypLE (Life Technologies), washed once in PBS, and then lysed in PBS by sonication. Cellular debris was cleared by centrifugation and the supernatant was used in plasmid digestion assays. For the digestions, lug tdTomato plasmid (Clontech) linearized by NdeI (New England Biolabs) was mixed with in vitro-transcribed tracrRNA, crRNA and 293FT cell lysate and incubated at 37° C. for 1-4 hours in digestion buffer (1x PBS with 10 mM MgCl2). DNA from the reaction mix was then purified with a PCR clean-up kit (Qiagen) and resolved by agarose gel electrophoresis. To map the cleavage site of NmCas9, the digested plasmid DNA was excised from the agarose gel and purified using Gel Extraction Kit (Qiagen). The purified fragments were then sequenced to map the cleavage site.
In Vitro Transcription. Synthetic oligonucleotides (Integrated DNA Technologies) containing the T7 promoter sequence and N. meningitidis tracrRNA or crRNA sequences were annealed to generate dsDNA templates for run-off transcription. In vitro transcription was done using the MegaScript T7 In Vitro Transcription kit (Ambion) following the manufacture's specifications.
Southern Blots. Genomic DNA of targeted clones is purified using PureGene core kit (Qiagen). 5 μg of genomic DNA was digested with BamHI and then resolved on a 0.8% agarose gel. DIG-labeled DNA probe synthesis, DNA gel transfer, and blot hybridization and visualization were done according to Roche's DIG application manual.
Genome editing using single-guide RNA (sgRNA). A single-guide RNA that targets tdTomato was put under the control of a U6 promoter and cloned into the EcoRV site of pstBlue-1 (Novagen). For electroporation, 7.5 μg of pstBlue-U6-sgRNA, 7.5 μg of pSimpleII-NLS-NmCas9-HA-NLS(s) and 5 μg of EBNA RNA was mixed with ˜1×106 cells in a 4 mm cuvette (BioRad) and immediately electroporated with a BioRad Gene Pulser. Cells were then plated into appropriate Matrigel coated culture dishes in E8™ medium supplemented with 10 μM ROCK inhibitor Y-27632.\
References for Example 2
1. Thomson J A, et al. (1998) Embryonic stem cell lines derived from human blastocysts. Science 282(5391):1145-1147.
2. Zwaka T P & Thomson J A (2003) Homologous recombination in human embryonic stem cells. Nat Biotechnol 21(3):319-321.
3. Urnov F D, Rebar E J, Holmes M C, Zhang H S, & Gregory P D (2010) Genome editing with engineered zinc finger nucleases. Nat Rev Genet 11(9):636-646.
4. Joung J K & Sander J D (2013) TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol 14(1):49-55.
5. Hockemeyer D, et al. (2009) Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol 27(9):851-857.
6. Hockemeyer D, et al. (2011) Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 29(8):731-734.
7. Zou J, et al. (2009) Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 5(1):97-110.
8. Zhang L, et al. (2000) Synthetic zinc finger transcription factor action at an endogenous chromosomal site. Activation of the human erythropoietin gene. J Biol Chem 275(43):33850-33860.
9. Cermak T, et al. (2011) Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res 39(12):e82.
10. Porteus M H (2006) Mammalian gene targeting with designed zinc finger nucleases. Mol Ther 13(2):438-446.
11. Barrangou R, et al. (2007) CRISPR provides acquired resistance against viruses in prokaryotes. Science 315(5819):1709-1712.
12. Bikard D, Hatoum-Aslan A, Mucida D, & Marraffini L A (2012) CRISPR interference can prevent natural transformation and virulence acquisition during in vivo bacterial infection. Cell Host Microbe 12(2):177-186.
13. Marraffini L A & Sontheimer E J (2008) CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. Science 322(5909):1843-1845.
14. Zhang Y, et al. (2013) Processing-Independent CRISPR RNAs Limit Natural Transformation in Neisseria meningitidis. Mol Cell 50(4):488-503.
15. Makarova K S, et al. (2011) Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol 9(6):467-477.
16. Brouns S J, et al. (2008) Small CRISPR RNAs guide antiviral defense in prokaryotes. Science 321(5891):960-964.
17. Hale C, Kleppe K, Terns R M, & Terns M P (2008) Prokaryotic silencing (psi)RNAs in Pyrococcus furiosus. RNA 14(12):2572-2579.
18. Wiedenheft B, Sternberg S H, & Doudna J A (2012) RNA-guided genetic silencing systems in bacteria and archaea. Nature 482(7385):331-338.
19. Garneau J E, et al. (2010) The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 468(7320):67-71.
20. Westra E R, et al. (2012) CRISPR immunity relies on the consecutive binding and degradation of negatively supercoiled invader DNA by Cascade and Cas3. Mol Cell 46(5):595-605.
21. Cong L, et al. (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339(6121):819-823.
22. Jinek M, et al. (2013) RNA-programmed genome editing in human cells. Elife 2:e00471.
23. Mali P, et al. (2013) RNA-guided human genome engineering via Cas9. Science 339(6121):823-826.
24. Wang H, et al. (2013) One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering. Cell 153(4):910-918.
25. Cho SW, Kim S, Kim JM, & Kim JS (2013) Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 31(3):230-232.
26. Chang N, et al. (2013) Genome editing with RNA-guided Cas9 nuclease in zebrafish embryos. Cell Res 23(4):465-472.
27. DiCarlo J E, et al. (2013) Genome engineering in Saccharomyce cerevisiae using CRISPR-Cas systems. Nucleic Acids Res 41(7):4336-4343.
28. Gratz S J, et al. (2013) Genome engineering of Drosophila with the CRISPR RNA-guided Cas9 nuclease. Genetics.
29. Hwang W Y, et al. (2013) Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol 31(3):227-229.
30. Xiao A, et al. (2013) Chromosomal deletions and inversions mediated by TALENs and CRISPR/Cas in zebrafish. Nucleic Acids Res.
31. Ding Q, et al. (2013) Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell 12(4):393-394.
32. Deltcheva E, et al. (2011) CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471(7340):602-607.
33. Gasiunas G, Barrangou R, Horvath P, & Siksnys V (2012) Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci USA 109(39):E2579-2586.
34. Jinek M, et al. (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337(6096):816-821.
35. Sapranauskas R, et al. (2011) The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli. Nucleic Acids Res 39(21):9275-9282.
36. Karvelis T, et al. (2013) crRNA and tracrRNA guide Cas9-mediated DNA interference in Streptococcus thermophilus. RNA Biol 10(5).
37. Shah S A, Erdmann S, Mojica F J, & Garrett RA (2013) Protospacer recognition motifs: Mixed identities and functional diversity. RNA Biol 10(5).
38. Deveau H, et al. (2008) Phage response to CRISPR-encoded resistance in Streptococcus thermophilus. J Bacteriol 190(4):1390-1400.
39. Horvath P, et al. (2008) Diversity, activity, and evolution of CRISPR loci in Streptococcus thermophilus. J Bacteriol 190(4):1401-1412.
40. Mojica F J, Diez-Villasenor C, Garcia-Martinez J, & Almendros C (2009) Short motif sequences determine the targets of the prokaryotic CRISPR defence system. Microbiology 155(Pt 3):733-740.
41. Kameda T, Smuga-Otto K, & Thomson J A (2006) A severe de novo methylation of episomal vectors by human ES cells. Biochem Biophys Res Commun 349(4):1269-1277.
42. Ren C, et al. (2006) Establishment and applications of epstein-barr virus-based episomal vectors in human embryonic stem cells. Stem Cells 24(5):1338-1347.
43. Chen G, et al. (2011) Chemically defined conditions for human iPSC derivation and culture. Nat Methods 8(5):424-429.
44. Fu Y, et al. (2013) High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol.
Reference is made to
In the foregoing description, it will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention. Thus, it should be understood that although the present invention has been illustrated by specific embodiments and optional features, modification and/or variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention. Citations to a number of patent and non-patent references are made herein. The cited references are incorporated by reference herein in their entireties. In the event that there is an inconsistency between a definition of a term in the specification as compared to a definition of the term in a cited reference, the term should be interpreted based on the definition in the specification.
Helicobacter musteiae 12198
Campylobacter jejuni subsp- jujuni NCTC 11168
Neisseria meningitidis 22491
Hyobacter polytrapus DSM 2926
Pasturella muitocicia subsp- multocida str- Pm70
Clostridium cellutolyticum H10
Rhodopseudomomas palustris BlsB18
Azospirillum sp. B510a
Candidatus Puniceispirillum marinum IMCC1322a
Parvibaculum lavamentivarans DS-1
Type II-C CRISPR/cas prediction
Species with CRISPRdb entry (http:/crispr.u-psud.fr/)
bSpecies without CRISPRdb entry but available genome sequences to predict CRISPR repeats
experimentally confirmed extended −10 box
indicates data missing or illegible when filed
et al.,
land in N. meningitidis Z2491
filamentous
toxin-like
gene-inventing
(Neisseria filamentous) prophages
gene-inverting protein
ML)
25
gene-inverting protein
ML)
protein
2 prophages in N. meningitidi
toxin-like
gene-investing protein
L)
and nearby degenerate Nf
)
=
FA
:
=
toxin-like,
related gene 3
1_sp2
=
=
toxin-like,
related gene 5 (
),
=
=
toxin-
,
gene 6 (
),
=
toxin-like,
with partially
related gene
(
)
related gene 4 (
)
FA1095
related gene 8 (
)
)
ML)
ML)
ML)
ML)
indicates data missing or illegible when filed
(a)Indicates antibiotic used to select transformants.
(b)The average and standard error of the mean (s.e.m.) of transformation frequencies (ratios comparing transformants cfu/ml vs. total cfu/ml) from at least three independent experiments.
(c)The rnc::Tn mutant of N. meningitidis 8013 exhibited obvious slow-growth defects.
indicates data missing or illegible when filed
N. meningitidis
N. lactamica
(a)according to Neisseria PubMLST database (Jolley and Maiden, 2010)
(b)according to CRISPRdb
(c)NC_013016_1 and NC_013016_2 each constitute part of our predicted CRISPR in N. meningitidis alpha14.
gttcagcgtgtccggcgagggcgaGTTGTAGCTCCCTTTCTCATTTCG
GacctggagtttgtgccagggtttGTTGTAGCTCCCTTTCTCATTTCG
gtacgtgaagcaccccgccgacatGTTGTAGCTCCCTTTCTCATTTCG
GccccgagggcttcaagtgggagcGTTGTAGCTCCCTTTCTCATTTCG
ggacggcggtctggtgaccgtgacGTTGTAGCTCCCTTTCTCATTTCG
gattacaagaagctgtccttccccGTTGTAGCTCCCTTTCTCATTTCG
GggcctcccagcccatggtcttctGTTGTAGCTCCCTTTCTCATTTCG
ggccgcccctacgagggcacccagGTTGTAGCTCCCTTTCTCATTTCG
The present application is a continuation of U.S. application Ser. No. 14/285,252, filed May 22, 2014, which claims the benefit of priority under 35 U.S.C. 119(e) to U.S. Provisional Patent Application No. 61/826,338, filed on May 22, 2013, the contents of each are incorporated herein by reference in their entireties.
| Number | Date | Country | |
|---|---|---|---|
| 61826338 | May 2013 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 14285252 | May 2014 | US |
| Child | 18058419 | US |
